Allosteric Modulators for
Human Health
Annual Report 2014
Page 1 of 52
Addex Therapeutics Annual Report 2014
Contents
3
4
6
15
18
44
Letter to Shareholders
Financial Review
Corporate Governance Report
Compensation Report
Consolidated Financial Statements
Statutory Financial Statements
Key Facts / Addex Therapeutics
Focus:
Disease area:
Lead programs:
Oral small molecule allosteric modulation-based drug discovery and
development against diseases with high unmet medical needs.
Rare diseases with orphan drug designation potential
Central Nervous System (CNS)
Dipraglurant (ADX48621) for the treatment of Parkinson’s disease
levodopa-induced dyskinesia (PD-LID);
Dipraglurant (ADX48621) for the treatment of dystonia;
ADX71149 for an undisclosed CNS disorders (licensed to Janssen
Pharmaceuticals Inc.);
ADX71441 for the treatment of Charcot-Marie-Tooth type 1A
neuropathy; and
ADX71441 for the treatments of addiction (alcohol use disorder
and/or nicotine cessation)
Total full time equivalent employees and
consultants as of December 31, 2014:
5
Stock symbol / exchange:
ADXN (ISIN:CH0029850754) / SIX Swiss Exchange
Shares outstanding as of 30 April 2015:
11,699,612
Cash as of December 31, 2014:
CHF2.0 million
Capital increase of CHF2.8 million executed 9 March 2015
Headquarters:
Geneva, Switzerland
Page 2 of 52
Addex Therapeutics Annual Report 2014
Letter to Shareholders
Dear Shareholders,
Addex has made significant progress in 2014, achieving important milestones as we execute our strategy to rebuild the Company
into a successful clinical stage drug developer. We completed a strategic review of our portfolio of allosteric modulator drug
candidates and took the decision to restart development of our two unpartnered clinical stage programs, dipraglurant and
ADX71441. We are also pursuing strategic alternatives for our preclinical portfolio and technologies. At the same time we continue
to develop strategic alliances with patient advocacy groups, academic institutions and governmental organizations to advance the
development of our exciting portfolio of drug candidates for the benefit of patients.
The results of our strategic review confirmed the promise of our portfolio of first in class drug candidates and the leading position of
our allosteric modulator drug discovery platform. With the support of The Michael J. Fox foundation for Parkinson’s Research, we
took the decision to restart the development of dipraglurant, a first in class negative allosteric modulator (NAM) of the metabotropic
glutamate receptor 5 (mGluR5), for the treatment of Parkinson’s disease levodopa induced dyskinesia (PD-LID,). Development of
dipraglurant in PD-LID has resumed with the initiation of a receptor occupancy study in healthy volunteers at the Johns Hopkins
University, in the United States, while in parallel we are preparing the development plans for a phase IIb study.
As part of our strategy to develop dipraglurant in dystonia, we entered a collaboration, with the Dystonia Medical Research
Foundation to prepare a phase IIa proof of concept clinical study in a rare form of dystonia. In parallel, we are working with
Professor Dirk Dressler of The Hanover Medical School to run a compassionate use pilot study with dipraglurant in cervical
dystonia, which we plan to complete in 2015.
Our other lead drug candidate ADX71441, a GABAB positive allosteric modulator (PAM) is currently involved in three major
collaborations. The Charcot-Marie-Tooth association is evaluating ADX71441 for the treatment of the rare neuropathy, Charcot-
Marie-Tooth type 1A (CMT1A), in a battery of preclinical models of the disease. The potential utility of ADX71441 for the treatment
of addiction has attracted the National Institute on Alcohol Abuse and Alcoholism (NIAAA) to evaluate ADX71441 in preclinical
models of alcohol use disorder and the National Institute on Drug Abuse (NIDA) to evaluate ADX71441 in preclinical models of
cocaine and nicotine addiction. In 2014, under our collaboration with NIDA, we reported positive results in preclinical models of
nicotine addiction with ADX71441.
Our strategic partner, Janssen Pharmaceuticals Inc., (JPI) reported in February 2014 that a phase II study with ADX71149 in major
depressive disorder patients with significant anxiety symptoms did not meet the primary end point. JPI continues to explore other
indications for the program. In December 2014, we announced receiving USD757,000 from JPI following the amendment of our
license and collaboration agreement. Under this amendment, certain jointly owned patents have been assigned to JPI and all past
patent costs paid by Addex have been reimbursed. Going forward, Addex contribution to patent costs has been significantly
reduced while the amendment has no impact on Addex right to receive royalties and milestones under the agreement.
In March of 2015, we executed a capital increase, raising CHF2.8 million of additional financing, extending our cash runway i nto
2017. Looking forward in 2015, we will complete the preparation of dipraglurant to enter a phase IIb study in PD-LID, complete a
pilot study with dipraglurant in cervical dystonia and prepare dipraglurant for a phase IIa study in a rare form of dystonia. We will
also initiate the phase 1 program for ADX71441 and start preparation for phase II studies in CMT1A and addiction. We will continue
to evaluate strategic options for our portfolio of drug candidate and pursue collaborations with industry, patient advocacy groups,
academic institutions and governmental organizations to advance their development for the benefit of patients.
We believe 2015 will be an important year for Addex as we restart clinical studies with dipraglurant and ADX71441. We have a
robust pipeline and are focused on executing our strategy to rebuild the Company into a successful clinical stage drug developer
based on our leading allosteric modulator drug discovery platform. We are committed to building significant value for our
shareholders and believe our ability to execute a clinical and regulatory strategy can drive this value. Finally, we would like to
acknowledge and thank all our employees, consultants and collaboration partners for their hard work, dedication, loyalty and
perseverance in executing the rebuilding of Addex. We would also like to thank you, our shareholders, for your continued support.
Vincent Lawton
Chairman of the Board
Tim Dyer
Chief Executive Officer
Page 3 of 52
Addex Therapeutics Annual Report 2014
Financial Review 2014
Overview
The following review and discussion of the financial results for 2014 should be read in conjunction with the consolidated financial
statements and related notes, which have been prepared in accordance with International Financial Reporting Standards and are
presented in this Annual Report.
We are a development-stage biopharmaceutical company focused on building a sustainable pharmaceutical business around our
expertise in the discovery and development of oral small molecule allosteric modulators of G-protein coupled receptors. As a result,
commercialization is currently limited to out-licensing of selected discovery and development stage programs.
During 2014, we completed a strategic review of our portfolio of drug candidates, and prepared dipraglurant and ADX71441 for
restarting clinical development. In addition we entered a number of collaborations with patient advocacy groups, academic
institutions and governmental organizations to both characterize our portfolio of drug candidates in various indications and to
provide expert opinion on the development and regulatory strategy. At December 31, 2014, our headcount was 5 FTEs compared
to 5 FTEs at December 31, 2013, and our average headcount was stable at 5 FTEs in 2014, compared to 30 FTEs in 2013.
Our 2014 research and development expenditure decreased to CHF0.9 million and our general and administrative expenses were
reduced to CHF1.6 million. CHF0.7 million has been recognized as income in the year and our net loss was significantly reduced to
CHF1.8 million. We ended the year with a cash position of CHF2.0 million.
Results of operations
The following table presents our consolidated results of operations for the fiscal years 2014 and 2013:
Amounts in millions of Swiss francs
Income
Research and development expenses
General and administrative expenses
Total operating expenses
Operating loss
Finance result, net
Net loss for the year
2014
0.7
(0.9)
(1.6)
(1.8)
(1.8)
-
(1.8)
2013
0.1
(9.3)
(5.3)
(14.5)
(14.5)
-
(14.5)
Income
Income has increased significantly in 2014 to CHF0.7 million, compared to CHF0.1 million in 2013 primarily due to an amount
received from our strategic partner, Janssen Pharmaceuticals Inc., following the amendment of our collaboration and license
agreement. 2013 income comprises an amount recognized under a research grant from The Michael J. Fox Foundation for
Parkinson’s Research. This grant was provided to support dipraglurant development in Parkinson’ disease levodopa-induced
dyskinesia.
Research and development expenses
R&D expenses have decreased by 90% to CHF0.9 million in 2014, compared to CHF9.3 million in 2013, mainly due to a significant
reduction in headcount following the decision to put on hold the majority of R&D activities in 2013, while the Group secured its
financial position. R&D expenses consist primarily of costs associated with research, preclinical and clinical testing and related staff
costs. They also include depreciation of laboratory equipment and leasehold improvements, costs of materials used in research,
costs associated with renting and operating facilities and equipment, as well as fees paid to consultants, patent costs and other
outside service fees and overhead costs. These expenses include costs for proprietary and third party R&D.
General and administrative expenses
G&A expenses have decreased by 70% to CHF1.6 million in 2014, compared to CHF5.3 million in 2013, primarily due to the
headcount reduction following the restructuring of the Group. G&A expenses consist primarily of staff costs, professional fees for
legal, tax and strategic purposes and overheads related to general management, human resources, finance, information
technology, business development and communication functions.
Net loss for the year
The net loss for the year has decreased by 88% to CHF1.8 million for 2014, compared to CHF14.5 million for 2013, mainly due to
the significant reduction in our operating expenses. Basic and diluted loss per share also decreased accordingly to CHF0.18 for
2014, compared to CHF1.60 for 2013.
Page 4 of 52
Addex Therapeutics Annual Report 2014│Financial Review
Balance sheet & cash flows
Cash and cash equivalents decreased by 33% to CHF2.0 million at December 31, 2014, compared to CHF2.9 million at December
31, 2013. This decrease of CHF0.9 million is mainly due to the net cash used in operations of CHF1.8 million offset by cash inflows
of CHF0.4 million from the sale of property, plant and equipment and CHF0.5 million from the sale of treasury shares.
There was no investment in property, plant and equipment during 2014 or 2013. The net book value of property, plant and
equipment decreased by 75% to CHF44,677 at December 31, 2014 compared to CHF179,524 at December 31, 2013, primarily due
to the annual depreciation charge as well as the disposal of certain assets.
Total shareholders’ equity has decreased to CHF2.3 million at December 31, 2014 compared to CHF3.0 million at December 31,
2013, mainly due to the net loss for the year.
Shares and shareholders’ information
At both December 31, 2014 and December 31, 2013, the Company had 10,173,576 outstanding issued shares and a free float of
100%. Of the outstanding issued shares at December 31, 2014, 188,688 shares were held in treasury (at December 31, 2013:
330,329 shares). During the 2014, 141,641 treasury shares were sold raising gross proceeds of CHF468,329. Our share price
performance was disappointing in 2014 and our closing share price and market capitalization decreased to CHF2.32 and CHF23.6
million at December 31, 2014, compared to CHF3.72 and CHF37.8 million at December 31, 2013, respectively.
2015 outlook
Following a strategic review of our portfolio in 2014, we took the decision to restart clinical development of dipraglurant with the
support of The Michael J. Fox Foundation for Parkinson’s Research and prepare ADX71441 for the start of phase I. We also
continue to pursue collaborations with industry, patient advocacy groups, academic institutions and governmental organizations to
drive forward our portfolio of exciting allosteric modulator drug candidates. In parallel, we will execute our strategy to secure the
resources necessary to advance the pipeline for the benefit of patient while maximizing value for our shareholders.
On March 9, 2015, the Group issued 1,526,036 new shares from authorized capital in a private placement of which 921,667 were
placed at CHF3 with investors, raising CHF2.8 million and 604,369 were placed at CHF1 with Addex Pharma SA, a subsidiary of
Addex. These shares are recorded as treasury shares and will be used to both raise additional funds and purchase services under
the share purchase plan.
Page 5 of 52
Addex Therapeutics Annual Report 2014
Corporate Governance Report 2014
General information
Addex’ Articles of Association (“Articles”), Organizational Rules and Policies provide the basis for the principles of Corporate
Governance. On January 1, 2014, the Ordinance against Excessive Compensation in Public Companies (“Compensation
Ordinance”) came into effect. The Compensation Ordinance implements a constitutional amendment based on a popular initiative
regarding executive compensation that was approved by the Swiss electorate in 2013. This report has been prepared in
accordance with the SIX Swiss Exchange Directive on Information Related to Corporate Governance effective as of October 1,
2014.
Group structure
Description of Addex’ operational group structure
Addex Therapeutics Ltd (“Addex” or the “Company”) is the holding and finance company of the Group. Addex Pharma SA, based in
Plan-les-Ouates, Geneva, Switzerland, a 100% subsidiary of Addex Therapeutics Ltd, is in charge of research, development,
registration, commercialization and holds the Group’s intellectual property. Addex Pharma SA has a share capital of CHF3,987,492
divided into 3,987,492 registered shares with a nominal value of CHF1 each. Addex Pharmaceuticals France SAS, based in
Archamps, France, a 100% subsidiary of Addex Pharmaceuticals Ltd performs research and development services for the Group.
Addex Pharmaceuticals France SAS has a share capital of EUR37,000 divided into 37,000 registered shares with a nominal value
of EUR1 each.
Listed company
Addex Therapeutics Ltd has its registered office c/o Addex Pharma SA, Chemin des Aulx 12, CH-1228 Plan-les-Ouates, Geneva,
Switzerland. Its shares have been listed on the SIX Swiss Exchange (SIX) since May 21, 2007 under the Swiss security number
(Valorennummer) 2985075. The ISIN is CH0029850754, the common code is 030039254 and the ticker symbol is ADXN. On
December 31, 2014, the market capitalization of Addex was CHF23,602,696.
Significant shareholders
As far as can be ascertained from the information available, the following shareholders own 3% or more of the Company’s share
capital as at December 31, 2014 based on published notifications to the on SIX:
Shareholder
BVF Partners L.P.1
Sofinnova Capital IV FCPR2
Tim Dyer
1BVF Partners L.P., 900 North Michigan Avenue, Suite 1100, Chicago, Illinois, 60611, USA. BVF Partners L.P. comprises Biotechnology Value Fund L.P., Biotechnology Value Fund II
L.P., Samana Capital L.P. and Investment 10 L.L.C.
2Sofinnova Capital IV FCPR has its principal office at 18, rue du 4 Septembre, 75002 Paris, France.
3Tim Dyer, Gland, Switzerland holding assumes exercise of all equity incentive units.
Number of shares
2 503 849
311 667
594 906
% of capital
24.61%
3.06%
5.85%
For a comprehensive list of notifications of shareholdings received during 2014 pursuant to article 20 of the Swiss Federal Act on
(www.six-swiss-
refer
Stock Exchanges and Securities Trading
exchange.com/shares/companies/major_shareholders_en.html).
the SIX Swiss Exchange website
(“SESTA”)
to
Cross-shareholdings
There are no cross-shareholdings in terms of capital shareholdings or voting rights in excess of 5%.
Page 6 of 52
Addex Therapeutics Annual Report 2014│Corporate Governance Report
Shareholder structure
There were 2,142 shareholders registered in the share register on December 31, 2014. The distribution of shareholdings is divided
as follows:
Number of shares
1 to 100
101 to 1,000
1,001 to 10,000
10,001 to 100,000
100,001 to 1,000,000
1,000,001 to 10,000,000
Number of registered shareholders on December 31, 2014
329
1044
699
66
4
0
The shareholder base on December 31, 2014 was constituted as follows:
Shareholder structure according to category of investors
(weighted by number of shares)
Private persons
Institutional shareholders
Not registered
37.66%
18.82%
43.52%
Shareholder structure by country
(weighted by number of shares)
United States
Switzerland
France
Germany
Other
Not registered
12.10%
41.76%
0.25%
0.10%
2.27%
43.52%
Capital structure
As of December 31, 2014, the share capital amounted to CHF10,173,576 consisting of 10,173,576 registered shares with a nominal
value of CHF1 per share. The share capital is fully paid up. As of December 31, 2014, the Company, indirectly, held 188,688 of its
own shares. These shares are recorded as treasury shares.
Authorized share capital
As of December 31, 2014 and according to the Articles, the Board of Directors (Board) is authorized, at any time until June 27, 2016
to increase the share capital in an amount of CHF5,086,788 through the issuance of 5,086,788 fully paid registered shares with a
nominal value of CHF1 each. An increase in partial amounts is permitted. The Board shall determine the issue price, the type of
payment, the date of issue of new shares, the conditions for the exercise of pre-emptive rights and the beginning date for dividend
entitlement. In this regard, the Board may issue new shares by means of a firm underwriting through a banking institution, a
syndicate or another third party with a subsequent offer of these shares to the current shareholders (unless the pre-emptive rights
of current shareholders are excluded). The Board may permit pre-emptive rights that have not been exercised to expire or it may
place these rights and/or shares as to which pre-emptive rights have been granted but not exercised, at market conditions or use
them for other purposes in the interest of the Company.
The subscription and acquisition of the new shares, as well as each subsequent transfer of the shares, shall be subject to the
restrictions of Article 5 of the Articles.
The Board is authorized to restrict or exclude the pre-emptive rights of shareholders and allocate such rights to third parties if the
shares are to be used (1) for the acquisition of enterprises, parts of an enterprise, or participations, or for new investments, or, in
case of a share placement, for the financing or refinancing of such transactions; or (2) for the purpose of the participation of
strategic partners (including in the event of a public tender offer) or for the purpose of an expansion of the shareholder constituency
in certain investor markets; or (3) for the granting of an over-allotment option (Greenshoe) of up to 20 percent to the banks involved
in connection with a placement of shares; or (4) for raising capital in a fast and flexible manner, which would not be achieved
without the exclusion of the statutory pre-emptive rights of the existing shareholders.
Conditional share capital
According to the Articles, the share capital of the Company may be increased by a maximum aggregate amount of CHF2,000,000
through the issuance of a maximum of 2,000,000 registered shares, which shall be fully paid-in, with a par value of CHF1 per share
by the exercise of option rights or subscription rights attached to bons de jouissance which the employees, directors and/or
consultants of the Company or a group company are granted according to respective regulations of the Board. The pre-emptive
rights of the shareholders are excluded. The acquisition of registered shares through the exercise of option rights or subscription
Page 7 of 52
Addex Therapeutics Annual Report 2014│Corporate Governance Report
rights granted to the holders of bons de jouissance and the subsequent transfer of the registered shares shall be subject to the
transfer restrictions provided in Article 5 of the Articles.
The share capital of the Company may be increased by a maximum aggregate amount of CHF3,086,788 through the issuance of a
maximum of 3,086,788 registered shares, which shall be fully paid-in, with a par value of CHF1 per share by the exercise of option
and/or conversion rights which are granted in connection with the issue of bonds, similar obligations or other financial instruments
by the Company or another group company. In the case of the issue of bonds, similar obligations or other financial instruments
linked with option and/or conversion rights, the pre-emptive right of shareholders is excluded. The holders of option and/or
conversion rights are entitled to receive the new shares. The Board shall determine the terms of the option and/or conversion rights.
The acquisition of registered shares through the exercise of option or conversion rights and the subsequent transfer of the
registered shares shall be subject to the transfer restrictions provided in Article 5 of the Articles.
The Board is authorized to restrict or exclude the pre-emptive rights of shareholders (1) if the debt or other financial instruments issued
with conversion rights or warrants are for the purpose of financing or refinancing of the acquisition of enterprises, parts of an enterprise,
or participations or new investments; or (2) if such debt or other financial instruments are issued on the national or international capital
markets and for the purpose of a firm underwriting by a banking institution or a consortium of banks with subsequent offering to the
public. If the advance subscription rights are excluded by the Board, the following shall apply: the issuance of convertible bonds or
warrants or other financial market instruments shall be made at the prevailing market conditions (including dilution protection provisions
in accordance with market practice) and the new shares shall be issued pursuant to the relevant conversion or exercise rights in
connection with bond or warrant issue conditions. Conversion rights may be exercised during a maximum 10-year period, and warrants
may be exercised during a maximum 7-year period, in each case from the date of the respective issuance.
Changes in capital
On March 6, 2015, Addex increased its share capital by CHF1,526,036 (1,526,036 registered shares with a nominal value of CHF1
per share) out of its authorized share capital in connection with a private placement to institutional investors, excluding the pre-
emption rights of shareholders in order to raise capital in a fast and flexible manner.
On August 9, 2013, Addex increased its share capital by CHF1,170,612 (1,170,612 registered shares with a nominal value of CHF1
per share) out of its authorized share capital in connection with a private placement to institutional investors, excluding the pre-
emption rights of shareholders in order to raise capital in a fast and flexible manner.
For further information on changes in capital in 2014 and 2013, including changes in reserves, refer to the consolidated statements
of changes in equity as well as note 14 of the consolidated financial statements and note 8 of the financial statements included in
this annual report.
Shares, participation and equity sharing certificates
Addex has one class of shares, i.e. registered shares with a nominal value of CHF1 per share. Each share is fully paid up and
carries one vote and equal dividend rights, with no privileges. The Company has 1,700 outstanding equity sharing certificates (Bon
de Jouissance / Genussscheine). Equity sharing certificates are available for granting to employees and/or directors of the Group
under the Group’s equity incentive plan. Equity sharing certificates do not form part of the share capital, have no nominal value, and
do not grant any right to vote nor the right to attend meetings of shareholders. Each equity sharing certificate grants the right to
subscribe for 1,000 shares of the Company and a right to liquidation proceeds of the Company calculated in accordance with Article
25 of the Articles. The Company has no participation certificates.
The Company’s shares and equity sharing certificates are not certificated. Shareholders and equity sharing certificate holders are
not entitled to request printing and delivery of certificates, however, any shareholder or equity sharing certificate holder may at any
time request the Company to issue a confirmation of their holdings.
Limitations on transferability of shares and nominee registration
A transfer of uncertified shares is affected by a corresponding entry in the books of a bank or depository institution following an
assignment in writing by the selling shareholder and notification of such assignment to Addex by the bank or the depository
institution. A transfer of shares further requires that a shareholder files a share registration form in order to be registered in Addex’
share register with voting rights. Failing such registration, a shareholder may not vote at or participate in a shareholders’ meeting.
A purchaser of shares will be recorded in Addex’ share register as a shareholder with voting rights if the purchaser discloses its
name, citizenship or registered office and address and gives a declaration that it has acquired the shares in its own name and for its
own account.
Addex’ Articles provide that a person or entity that does not explicitly state in its registration request that it will hold the shares for its
own account (Nominee) may be entered as a shareholder in the share register with voting rights for shares up to a maximum of 5%
of the share capital as set forth in the commercial register. Shares held by a Nominee that exceed this limit are only registered in
the share register with voting rights if such Nominee declares in writing to disclose the name, address and shareholding of any
person or legal entity for whose account it is holding 1% or more of the share capital as set forth in the commercial register. The
limit of 1% shall apply correspondingly to Nominees who are related to one another through capital ownership or voting rights or
have a common management or are otherwise interrelated. A share being indivisible, hence only one representative of each share
will be recognized. Furthermore, shares may only be pledged in favor of the bank that administers the bank entries of such shares
Page 8 of 52
Addex Therapeutics Annual Report 2014│Corporate Governance Report
for the account of the pledging shareholders. If the registration of shareholdings with voting rights was effected based on false
information, the Board may cancel such registration with retroactive effect.
Convertible bonds and options
As of December 31, 2014, the Company has no convertible or exchangeable bonds or loans outstanding. For information on equity
incentive plans for Non-Executive Directors, Executive Management and employees, refer to note 15 of the consolidated financial
statements included in this annual report.
Board of directors
The following table sets forth the name, year joined the Board, position and directorship term, as well as committee memberships,
of each member of the Board, all of whom are Non-Executive Directors, followed by a short description of each member’s business
experience, education and activities:
Name
Vincent Lawton
First Elected
2009
Elected until
2015
Board
Chairman
Vincent Lawton
Chairman
Professor Lawton was born in 1949 and is a U.K. citizen. He was Vice President Merck Europe and Managing Director of MSD UK
until he stepped down in 2006, after 26 years’ service internationally for Merck & Co Inc. He was appointed CBE (Commander of the
British Empire) by the Queen of England for services to the Pharmaceutical Industry. During his tenure, MSD UK achieved sustained
commercial success, launching many new medicines to the market in a wide range of therapeutic areas, becoming the fastest
growing company in the market over a number of years. He worked in commercial, research and senior management roles in France,
the US and Canada, Spain and throughout Europe. As President of the UK Industry Association, the ABPI, he negotiated industry
pricing, worked with Government bodies to help establish the UK Globally as a leading centre of clinical research. He is the Chairman
of Aqix Ltd, a private UK biotechnology company, member of the Board of the Medicines Regulator, the MHRA and is a Senior
Strategy Advisor for Imperial College Department of Medicine, University of London. He also serves as a consultant to a number of
leading healthcare organisations. He studied Psychology at the University of London and holds undergraduate and PhD.
Other activities and vested interests
The Addex’ Articles provide certain restrictions to the number mandates that members of the Board of Directors may have in the
supreme governing bodies of legal entities registered in the Swiss commercial register or similar foreign register as follows: 1) No
member of the Board of Directors may hold more than fifteen board of director mandates with no more than four mandates in listed
entities; 2) Mandates in companies controlled by Addex or which control Addex are not subject to restrictions; 3) Mandates that are
held by order and on behalf of Addex or companies under Addex control are restricted to ten; and 4) mandates in associations,
charitable organizations, family trusts and foundations relating to post-retirement benefits and other not-for-profit organizations are
restricted to twenty-five. Multiple mandates in different legal entities which are under common control are deemed to be one
mandate.
Apart from the information given above, none of the members of the Board of Directors has had other activities or holds any
positions of 1) in governing and supervisory bodies of important Swiss and foreign organizations, institutions and foundations under
private and public law; 2) permanent management and consultancy functions for important Swiss and foreign interest groups; or 3)
official government functions and political posts.
Additional mandates of members of the Board of Directors outside the Group
The Compensation Ordinance requires that as of the Annual General Meeting of June 11, 2015, Addex’ Articles govern the
maximum number of additional mandates held by members of the Board of Directors outside the Group. Addex’ Articles do not yet
contain such a provision. A proposal to amend the Articles will be submitted to the Annual General Meeting of June 11, 2015.
Elections and terms of office
Addex’ Articles provide for a Board consisting of between one and eleven members. The Company currently has one member of
the Board. In accordance with the Compensation Ordinance Members of the Board including the Chairman are appointed and
removed exclusively by shareholders’ resolution for a term of one year until completion if the next ordinary general meeting of
shareholders. A proposal to amend Addex’ Articles accordingly will be submitted to the Annual General Meeting of June 11, 2015.
Changes in the board of directors
At the shareholders meeting of June 27, 2014, André J. Mueller, Oleg Nodelman and Hoyoung Huh did not stand for re-election.
Internal organization and areas of responsibility
Addex’ Articles and Organizational Rules define the Company’s internal organization and areas of responsibility of the Board,
Chairman, CEO and the Executive Management.
Responsibilities of the board of directors
The Board is entrusted with the ultimate direction of the Company and the supervision of management. The Board’s non-
transferable and irrevocable duties include managing the Company and issuing the necessary directives, determining the
organization including adoption and revision of the Organizational Rules, organizing the accounting system, the financial controls,
Page 9 of 52
Addex Therapeutics Annual Report 2014│Corporate Governance Report
the financial and strategic planning, as well as appointing, recalling, setting remuneration and ultimately supervising the persons
entrusted with the management and representation of the Company, including the CEO. Furthermore, these duties include the
responsibility for the preparation of the annual report and the shareholders’ meetings, the carrying out of shareholders’ resolutions,
the notification of the judge in case of over indebtedness of the Company, and, passing resolutions regarding supplementary
contributions for shares not fully paid-in, increases in capital to the extent that such power is vested in the Board, and of resolutions
concerning the confirmation of capital increases and corresponding amendments to the Articles as well as making the required
report on capital increases.
In addition to these duties the Board specifically retains responsibility for the non-delegable and inalienable duties and powers
pursuant to the Swiss Merger Act and any other law; the examination of the necessary qualifications of the auditors; the adoption of,
and any amendments or modifications to any equity incentive plans; and the decisions regarding entering into any financing
arrangement in excess of CHF2 million including loan agreements, credit lines, letters of credit or capitalized leases; the issuance of
convertible debentures or other financial market instruments; and the approval of any recommendation made by any of the
Committees.
According to the current Organizational Rules enacted by the Board, resolutions of the Board are passed by way of simple majority
vote. To validly pass a resolution, more than half of the members of the Board have to attend the meeting. No quorum is required
for confirmation resolutions and adaptations of the Articles in connection with capital increases pursuant to articles 634a, 651a,
652g and 653g of the Swiss Federal Code of Obligations.
Chairman of the board of directors
The Chairman of the Board calls, prepares, and chairs the meetings of the Board. The Chairman also chairs the shareholders’
meetings. He supervises the implementation of the resolutions of the Board and generally supervises the CEO, who regularly
reports to the Chairman on the meetings of the Executive Management and all important matters of the Group.
Committees of the board of directors
The Board has one standing committee, the Audit Committee that was operational during the year 2014. The tasks and
responsibilities of this Committee are set forth in the Organizational Rules. This Committee makes proposals to the Board in its area
of responsibility while the resolutions are passed by the Board. On June 27, 2014, following Vincent Lawton being elected by the
shareholders as sole member of the Board and Chairman, the Audit Committee was disbanded.
Audit committee
Since June 27, 2014 the Audit Committee has been disbanded and its responsibilities have been assumed by the Board. Prior to
June 27, 2014, the Audit Committee included Vincent Lawton as sole member and Chairman. The Audit Committee assisted the
Board in fulfilling its duties of supervision of management. It was responsible for the guidelines for risk management and the internal
control system, review of the compliance system, review of the auditors’ audit plans, review of annual and interim financial
statements, monitoring of the performance and independence of external auditors (including authorizing non-audit services by the
auditors and their compliance with applicable rules), review of the audit results and monitoring of the implementation of their
findings by management.
In 2014, the Audit Committee held two meeting to review the full year 2013 financial statements and the 2014 first quarter balance
sheet and to generally review legal and regulatory compliance matters. The CEO and CFO were present at a portion of the
meetings.
Working methods of the board of directors
In 2014, the Board held six meetings with average duration of one half a day. The majority of meetings were held at the Company’s
offices with virtually full attendance at all meetings. In addition to formal Board meetings, the Board holds additional ad hoc
meetings or telephone conferences to discuss specific matters. The CEO is entitled to attend every Board meeting and to
participate in its debates and deliberations with the exception of non-executive sessions.
During Board meetings, each member of the Board may request information from the other members of the Board, as well as from
the members of the Executive Management present on all affairs of the Company. The CEO reports at each meeting of the Board
on the course of business of the Company in a manner agreed upon from time to time between the Board and the CEO. The
chairman of each Board Committee reports to the full Board at the Board meeting following the relevant Committee meeting. Any
resolutions on matters assigned to the Committees are taken by the Board on the basis of recommendations of the relevant
Committee.
In addition to reporting at Board meetings, the CEO reports immediately any extraordinary event and any significant change within
the Company to the Chairman. Outside of Board meetings, each member of the Board may request from the CEO information
concerning the course of business of the Company.
Definition of areas of responsibility
The Board has delegated all areas of management of the Group’s business to the CEO and the Executive Management, and has
granted the CEO the power to appoint the members of the Executive Management. The Board carries out the responsibilities and
duties reserved to it by law, the Articles and the Organizational Rules as detailed in section “Responsibilities of the board of
directors” on page 10.
Page 10 of 52
Addex Therapeutics Annual Report 2014│Corporate Governance Report
Information and control instruments of the board of directors
The Board ensures that it receives sufficient information from the CEO and Executive Management to perform its supervisory duty
and to make the decisions that are reserved to the Board. At each board meeting the Board receives reports from the CEO and
selected members of the Executive Management on the status of finance, business, research and development. These reports
focus on the main risks and opportunities related to the Group. In addition, the Board is provided with a status report prior to each
board meeting, a monthly finance report and other ad hoc reports on significant matters related to the Group’s operations.
Furthermore, the Board receives unaudited annual and interim financial statements for all group companies including consolidated
financial statements for the Company. The Board receives a written report from the auditors on the results of the audit which
includes any findings with respect to internal control risks arising as a result of their audit procedures. The auditor was invited to the
Audit Committee meeting two times and attended two meetings. Since the Audit Committee was disbanded on June 27, 2014, the
auditor has been invited once and attended once a meeting with the Board. Addex does not have an independent internal audit
function.
For further information on the risk management and the financial risks factors inherent to the Group’s activities, refer to note 3 of the
consolidated financial statements.
Executive management
In accordance with the Articles and the Organizational Rules, the Board has delegated the operational management to the CEO.
The CEO together with the Executive Management and under the control of the Board conducts the operational management of the
Company pursuant to the Organizational Rules and reports to the Board on a regular basis.
The following table sets forth the name, year of birth and principal position of those individuals who currently are part of the
Executive Management followed by a short description of each member’s business experience, education and activities:
Name
Tim Dyer
Sonia Poli
Year of Birth
1968
1965
Position
Chief Executive Officer
Chief Scientific Officer
Nationality
British
Italian
Tim Dyer
Chief Executive Officer
Since co-founding Addex in 2002, Mr Dyer has played a pivotal role in building the Addex Group, raising CHF276 million of capital,
including Addex IPO and negotiating licensing agreements with pharmaceutical industry partners that generated more than CHF50
million in cash inflows. Prior to founding Addex, he spent 10 years with Price Waterhouse (PW) & PricewaterhouseCoopers (PwC) in
the UK and Switzerland as part of the audit and business advisory group. At PwC in Switzerland, Mr Dyer’s responsibilities included
managing the service delivery to a diverse portfolio of clients including high growth start-up companies, international financial
institutions and venture capital and investment companies. At PW in the UK, Mr Dyer gained extensive experience in audit and
transaction support; spending two years performing inward investment due diligence on local financial institutions in the Ex-Soviet
Union. Mr Dyer has extensive experience in finance, corporate development, business operations and the building of start-up
companies and serves as a member of the Swiss government innovation promotion agency coaching team. Mr Dyer also serves on
the advisory board of the École polytechnique fédérale de Lausanne Management of Technology MBA program. He serves on the
boards of Abionic SA, a private medical device start-up company focused on in vitro allergy diagnostics and Qwane Biosciences SA, a
private drug development tool company focused on commercializing microelectrode array technologies. Mr Dyer is also founder and
managing partner of TMD Advisory, a CFO services company. He is a UK Chartered Accountant and holds a BSc (Hons) in
Biochemistry and Pharmacology from the University of Southampton, UK.
Sonia Poli
Chief Scientific Officer
Dr Poli, who joined Addex in 2004, is an accomplished drug developer with 18 years of international experience in large and small
pharmaceutical companies. At Addex, Dr Poli has provided preclinical support for ongoing clinical development programs and has
overseen the transition of four products into clinical development for indications including smoking cessation, anxiety, schizophrenia,
migraine, gastroesophageal reflux disease and Parkinson’s disease. Prior to joining Addex, she spent 8 years at Roche in the drug
metabolism and pharmacokinetics (DMPK) area, where she was a key inventor and global head of a multidimensional optimization
approach for drug discovery and development. In this role at Roche, she was an important contributor to selecting clinical candidates in
CNS indications, including Alzheimer’s disease, Parkinson’s disease, bi-polar disorders and anxiety. Dr. Poli serves on the board of
Dimerix Bioscience, a public unlisted clinical stage drug discovery and development company, based in Melbourne, Australia. Dr Poli
obtained her degree and doctorate in Industrial Chemistry at the University of Milan in 1993 and completed a post doctoral fellowship at
the CNRS, in Paris, in the group of Prof. D. Mansuy in 1997. Dr Poli is co-author of more than 40 research publications and several
patents.
Management contracts
There are no management contracts between Addex and third parties, except for the contract with TMD Advisory Ltd, a company
owned and managed by Mr. Dyer, that has been mandated to provide CEO / CFO services to the Addex Group.
Page 11 of 52
Addex Therapeutics Annual Report 2014│Corporate Governance Report
Additional mandates of members of the Executive Management outside the Group
The Compensation Ordinance requires that as of the Annual General Meeting of June 11, 2015, Addex’ Articles govern the
maximum number of additional mandates held by the Executive Management outside the Group. Addex’ Articles do not yet contain
such a provision. A proposal to amend the Articles will be submitted to the Annual General Meeting of June 11, 2015.
Other vested activities and vested interests
None of the members of the Executive Management has had other activities in governing and supervisory bodies of important
Swiss and foreign organizations, institutions and foundations under private and public law. No member of the Executive
Management has permanent management and consultancy functions for important Swiss and foreign interest groups, or holds any
official functions and political posts.
Changes in executive management
There have been no changes in the Executive Management during 2014.
Compensation, loans and shareholdings
Information about content and method of determining compensation and shareholder programs of the members of the Board of
Directors and Executive Management can be found in the Compensation Report of the Company. Information about shareholdings
of the members of the Board of Directors and Executive Management can be found in note 12 of the statutory financial statement of
the Company.
Shareholders’ participation
Voting rights and representation restrictions
Voting rights may be exercised only after a shareholder has been recorded in the Company’s share register as a shareholder or
usufructuary with voting rights. No exceptions from these restrictions were granted in 2014. A shareholder may be represented by
his legal representative, the corporate proxy, the independent proxy, by a depositary or by another shareholder. Subject to the
registration of shares in the share register within the deadline set from time to time by the Board before shareholders’ meetings, the
Company’s Articles do not impose any restrictions on the voting rights of shareholders. Specifically, there is no limitation on the
number of voting rights per shareholder. For further information on the conditions for registration in the share register (including in
relation to Nominees) and for attending and voting at a shareholders’ meeting, please refer to the sections “Limitations on
transferability of shares and nominee registration” on page 8 above and “Registration in the share register” on page 14 below.
Resolutions of shareholders’ meetings generally require the approval of the simple majority of the votes represented at the
shareholders meeting. Such resolutions include amendments to the Articles, elections of the members of the Board and statutory
and group auditors, approval of the annual financial statements, setting the annual dividend, decisions to discharge the members of
the Board and management for liability for matters disclosed to the shareholders’ meeting and the ordering of an independent
investigation into specific matters proposed to the shareholders’ meeting.
A resolution passed at a shareholders’ meeting with a qualified majority of at least two-thirds of the votes represented and the
absolute majority of the nominal share capital is required by law for: (i) changes to the business purpose; (ii) the creation of shares
with privileged voting rights; (iii) restrictions on the transferability of registered shares; (iv) an increase of the authorized or
conditional share capital; (v) an increase in the share capital by way of capitalization of reserves against contribution in kind, for the
acquisition of assets or involving the grant of special privileges; (vi) the restriction or elimination of pre-emptive rights of
shareholders; (vii) a relocation of the registered office, and (viii) the dissolution of the Company. Special quorum rules apply by law
to a merger, demerger, or conversion of the Company. The introduction or abolition of any provision in the Articles introducing a
majority greater than that required by law must be resolved in accordance with such greater majority.
Independent proxy
Addex' Articles do not contain a provision regarding election of the independent proxy by the Shareholders’ Meeting. The Board will
propose to the Annual General Meeting of June 11, 2015 to amend the Articles accordingly. Nevertheless, the Shareholders’
Meeting of June 27, 2014, elected Robert P. Briner as the independent proxy in line with the new requirements of the
Compensation Ordinance.
Statutory quorums
There is no provision in the Articles requiring a majority for shareholders’ resolutions beyond the majority requirements set out by
applicable legal provisions.
Convening of shareholders’ meetings and agenda items
The shareholders’ meeting is the supreme institution of the Company and under Swiss law, the ordinary shareholders’ meeting
takes place annually within six months after the close of the business year. Shareholders’ meetings may be convened by the Board
or, if necessary, by the auditors. Furthermore, the Board is required to convene an extraordinary shareholders’ meeting if so
requested in writing by holders of shares representing at least 10% of the share capital and who submit a petition specifying the
item for the agenda and the proposals. Shareholders representing shares with a nominal value of at least CHF1,000,000 or 10% of
the share capital have the right to request in writing that an item be included on the agenda of the next shareholders’ meeting,
setting forth the item and the proposal. A request to put an item on the agenda has to be made at least 60 days prior to the meeting.
Extraordinary shareholders’ meetings may be called as often as necessary, in particular in all cases required by law.
Page 12 of 52
Addex Therapeutics Annual Report 2014│Corporate Governance Report
A shareholders’ meeting is convened by publishing a notice in the Swiss Official Commercial Gazette (Feuille Officielle Suisse du
Commerce/Schweizerisches Handelsamtsblatt) at least 20 days prior to such meeting. In addition, holders of shares may be
informed by a letter sent to the address indicated in the share register.
Registration in the share register
The Board determines the relevant deadline for registration in the share register giving the right to attend and to vote at the
shareholders’ meeting. Such deadline is published by Addex on the Company’s website, usually in connection with the publication
of the invitation to the shareholders’ meeting in the Swiss Official Commercial Gazette.
The registration deadline for the ordinary shareholders’ meeting to be held on June 11, 2015 has been determined to be June 5,
2015.
Addex has not enacted any rules on the granting of exceptions in relation to these deadlines. No exceptions were granted in 2014,
and the Board does not anticipate granting any exceptions related to the shareholders’ meeting on June 11, 2015.
For further information on registration in the share register, please refer to section “Limitations on transferability of shares and
nominee registration” on page 8.
Changes of control and defense measures
Duty to make an offer
Swiss law provides for the possibility to have the Articles contain a provision which would eliminate the obligation of an acquirer of
shares, exceeding the threshold of 33 1/3% of the voting rights, to proceed with a public purchase offer (opting-out provision
pursuant to Article 22 para. 2 SESTA) or which would increase such threshold to 49% of the voting rights (opting-up provision
pursuant to Article 32 para. 1 SESTA). The Company’s Articles do not contain an opting-out or an opting-up provision.
Clauses on change of control
Addex’ equity sharing certificate equity incentive plan contains a provision in respect of changes of Addex shareholder base. In the
event of a change of control over Addex (defined as a change of control event triggering a mandatory public purchase offer
according to applicable stock exchange rules) all outstanding unexercised share options and subscription rights attached to equity
sharing certificates, vest, and in the case of subscription rights attached to equity sharing certificates, they become exercisable with
their remaining term being reduced proportionally.
Auditors
Duration of the mandate and term of office of the lead auditor
Pursuant to the Articles the auditor shall be elected every year and may be re-elected. The statutory and group auditors of Addex
are PricewaterhouseCoopers SA, Geneva, Switzerland. PricewaterhouseCoopers SA has held the function of statutory auditor
since inception of the Company in February 2007 and of Addex Pharma SA since its inception in 2002, and acts as group auditor
since 2004. The lead auditor of Addex since 2009 is Mr. Michael Foley.
Audit fees
In 2014, PricewaterhouseCoopers SA and its affiliates charged the Group audit fees in the amount of CHF90,000.
Additional fees
In 2014, PricewaterhouseCoopers SA and its affiliates charged the Group additional fees in the amount of CHF0.
Control instruments of the auditors
The Audit Committee was disbanded on June 27, 2014 and since this date the Chairman of the Board of Directors, Vincent Lawton
assumes the task of supervising the auditors. The Chairman meets with external auditors at least once a year to discuss the scope
and the results of the audit and to assess the quality of their service. The auditors prepare a management letter addressed to the
Chairman of the Board of Directors two times per year, informing them of their audit plan for the year under review followed by a
report detailing the result of their annual audit.
In 2014, the Audit Committee or Chairman of the Board, respectively, met with the auditors two times to discuss the scope and the
results of their year-end audit for 2013, the financial situation of the Group and half year financial statements, and the scope of the
2014 audit.
Information policy
Addex publishes financial results in the form of an Annual Report and a Half-year Report (Interim Report). In addition, Addex
informs shareholders and the public regarding the Group’s business through press releases, conference calls, as well as
roadshows. Where required by law or Addex’ Articles, publications are made in the Swiss Official Commercial Gazette. The Annual
Report, usually published no later than April of the following year, and the Interim Report, usually published no later than in August,
are both announced by press release. Annual Reports, Interim Reports and press releases are available on request in printed form
to all registered shareholders, and are also made available on the Group’s website at www.addextherapeutics.com. The Group’s
Page 13 of 52
Addex Therapeutics Annual Report 2014│Corporate Governance Report
website, which is the Group’s permanent source of information, also provides other information useful to investors and the public,
including information on the Group’s research and development programs as well as contact information. It is the Group’s policy not
to release explicit earnings projections, but it will provide general guidance to enable the investment community and the public to
better evaluate the Group and its prospective business and financial performance. The Board has issued a disclosure policy to
ensure that investors will be informed in compliance with the requirements of the SIX Swiss Exchange. The Group’s investor
relations department is available to respond to shareholders’ or potential investors’ queries under IR@addextherapeutics.com or via
post at Addex Therapeutics Ltd., Investor Relations, Chemin des Aulx 12, CH-1228 Plan-les-Ouates, Geneva, Switzerland.
Additional inquiries may also be made by phone at +41 22 884 1555.
Insider policy
The Board has issued an insider policy and implemented procedures to prevent insiders from benefiting from confidential
information. The policy defines guidelines on how to deter corporate insiders from making use of confidential information. The
Board has established blocking periods to prevent insiders from trading during sensitive periods.
Ethical business conduct
The Group is committed to the highest standards of ethical conduct. As a pharmaceutical business, the Group is operating in a
highly regulated business environment. Strict compliance with all legal and health authority requirements, as well as requirements
of other regulators, is mandatory. The Group expects its employees, contractors and agents to observe the highest standards of
integrity in the conduct of the Group’s business. The Code of Conduct sets forth the Group’s policy embodying the highest
standards of business ethics and integrity required of all directors, executives, employees and agents when conducting business
affairs on behalf of the Group. The Group is committed to complying with the spirit and letter of all applicable laws and regulations
where the Group engages in business.
Page 14 of 52
Addex Therapeutics Annual Report 2014
Compensation Report 2014
Overview
This Compensation Report provides the information required by the federal Ordinance against excessive compensation in listed
companies ("Compensation Ordinance") (effective as of January 1, 2014), which prevails over articles 663bbis and 663c paragraph
3 of the Swiss Code of Obligations. It also includes information required by section 5 of the Annex to the Directive on Information
relating to Corporate Governance of the SIX Swiss Exchange (effective date October 1, 2014) and the Swiss Code of Best Practice
for Corporate Governance (status August 28, 2014).
At the 2015 Annual General Meeting, the shareholders will be asked to approve amendments to Addex' Articles that are required to
comply with the Compensation Ordinance. The revised Articles include provisions related to the:
Principles of compensation
Shareholders’ binding vote on remuneration
Additional amount for members of the Executive Management hired after the vote on remuneration by the Shareholders’
Meeting
Loans and credit facilities for members of the Board of Directors and of the Executive Management
Review and approval process
The Board of Directors reviews compensation of its members and members of the Executive Management annually in accordance
with the Company’s Compensation Policy. In its review process the Board of Directors considers compensation packages of other
companies in the biotech and pharmaceutical industry in Switzerland and Europe that are comparable to Addex with respect to size
or business model, the professional experience and areas of responsibility of the respective members. The Board of Directors may
also consult relevant compensation surveys and bench marking reports. Based on its review, the Board of Directors submits two
proposals for approval at the shareholders meeting: (i) the maximum aggregate amount of fixed and variable compensation for the
Board of Directors for the prospective period from one ordinary general meeting of shareholders to the following ordinary general
meeting of shareholders; and (ii) the maximum aggregate amount of fixed and variable compensation for the Executive
Management for the period from January 1 to December 31 of the next financial year. Approval of these proposals requires an
absolute majority (more than 50% of the share votes represented at the shareholders meeting).
Compensation elements for the Board of Directors and Executive Management
Board of Directors
The compensation of the member of the Board of Directors consists of fixed and variable elements. The fixed element comprises a
fixed annual monetary compensation per board term from one general meeting of shareholders to the next. The variable element
comprises a monetary compensation based on board meeting attendance and equity incentive units (share options and equity
sharing certificates). Social security contributions of the Company are accrued on the fixed and variable elements. Board member
social security contributions are accrued on the fair value of equity incentive units. Equity incentive units are granted based on the
discretion of the Board of Directors. In addition, the Company reimburses members of the Board of Directors for out-of-pocket
expenses incurred in relation to their services on an on-going basis upon presentation of the corresponding receipts. The most
recent review of compensation for members of the Board of Directors took place on December 18, 2014. For further information on
the compensation for members of the Board of Directors, please refer to the section “Compensation of the Board of Directors in
2014 and 2013” on page 16.
Executive Management
The compensation of members of the Executive Management consists of fixed and variable elements. The fixed element may
include a base salary or a cash retainer paid under a consulting contract. The variable element may include performance-related
cash or share based bonuses, consulting fees based on chargeable hours and equity incentive units (equity sharing certificates and
stock options). Company contributions to pension plans, death and invalidity insurances and social security contributions are
accrued on all fixed and variable element compensation that relates to an employment relationship. Both company and employee
social security contributions are accrued for all shares or equity incentive unit compensation. The amount of the fixed element
depends on the position, responsibilities, experience and skills, and takes into account individual performance. The fixed element is
reviewed at the end of each year by the Board of Directors. Any changes in the fixed elements are made effective in January of the
following year. The variable elements are based on individual and company performance. The potential variable cash bonus is
determined in the employment contract and in general is a percentage of the base salary. Where the Executive Manager has been
engaged under a consulting contract, the variable element is based on the time spent at the contractually defined rate of
remuneration. At the beginning of each year the Board of Directors decides, on the total amount of variable element including the
amount of cash and equity incentive units to be granted for the previous year based on the achievement of Company goals. Equity
incentive units are granted based on the discretion of the Board. Variable cash compensation paid to Executive Managers in 2013
and 2014 relates to consulting fees.
Page 15 of 52
Addex Therapeutics Annual Report 2014│Compensation Report
Equity incentive plans
The purpose of the Company’s share purchase, share option and equity sharing certificate programs (refer to note 15 of the
consolidated financial statements) is to provide members of the Board of Directors, Executive Management, employees and certain
consultants with an opportunity to benefit from the potential appreciation in the value of the Company’s shares, thus providing an
increased incentive for participants to contribute to the future success and prosperity of the Company, enhancing the value of the
shares for the benefit of the shareholders of the Company and increasing the ability of the Company to attract and retain individuals
of exceptional skill. In addition, these plans provide the company with a mechanism to engage services for non-cash consideration.
The grant of any share option or equity sharing certificate is at the discretionary of the Board of Directors. Key factors considered by
the Board of Directors in making grants of share options or equity sharing certificates are the amount of shareholder approved
conditional capital, the benchmarking with other companies as well as individual performance. The strike price is determined by the
Board of Directors and is primarily based on the closing price of the Company’s shares on the SIX Swiss Exchange on the grant
date. The transfer of treasury shares under the share purchase plan to settle consulting services are based on predefined terms of
the consulting contract.
Indirect benefits
The Company may contribute to the pension plan and maintains certain insurance for death and invalidity for the members of the
Executive Management. New entrants may be eligible for reimbursement of relocation costs, compensation for lost benefits or stock
granted by a previous employer, international school for children or language courses for a limited time period. No Indirect benefits
have been paid to Executive Management in 2014. In 2013, relocation costs including accommodation in Geneva and repatriation
costs were paid to members of the Executive Management.
The Company has not granted any loans, credits or guarantees to members of the Board of Directors or of the Executive
Management in 2013 or 2014.
Compensation for the financial year under review
Compensation of the Board of Directors in 2014 and 2013
2014
Fixed
Variable compensation
CHF
Vincent Lawton……...……………………
Total……………………………………….
cash
compensation
26,573
26,573
cash
attendance
26,573
26,573
number of
equity
incentive
units(1)
100,000
100,000
value of
equity
incentive
units(1)
111,616
111,616
Total
2014
164,762
164,762
(1) Equity incentive units include share options granted under the 2014 share option plan and equity sharing certificates subscription rights that have been reprised (refer to note 15 of the
consolidated financial statements).
2013
Fixed
Variable compensation
CHF
André J. Mueller………………………….
Vincent Lawton….…...……………………
Hoyoung Huh……………………………..
Oleg Nodelman…………………………..
Total……………………………………….
cash
compensation
15,944
15,944
10,629
10,629
53,146
cash
attendance
15,944
10,629
10,629
10,629
47,831
number of
equity
incentive
units
0
0
0
0
0
value of
equity
incentive
units
0
0
0
0
0
Total
2013
31,888
26,573
21,258
21,258
100,977
Compensation to the Executive Management in 2014 and 2013
2014
Fixed
Variable compensation
CHF
Total Executive Management(1)….……..
cash
compensation
-
Cash(3)
580,000
number of
equity
incentive
units(2)
649,651
value of
equity
incentive
units(2)
785,247
Total
2014
1,365,247
(1) The highest paid member of Executive Management in 2014 was the CEO, Tim Dyer, who received CHF384,000 of variable cash compensation, 549,651 equity incentive units. The value of
equity incentive units including accrued social charges amounted to CHF667,824.
(2) Equity incentive units include share options granted under the 2014 share option plan, shares awarded for consulting services under the share purchase plan and reprised equity sharing
certificate subscription rights (refer to note 15 of the consolidated financial statements).
(3) Executive managers have been engaged under consulting contracts which include hourly and daily rates with a monthly cap.
Page 16 of 52
Addex Therapeutics Annual Report 2014│Compensation Report
2013
Fixed(2)
Variable compensation
CHF
Total Executive Management(1)………….
cash
compensation
2,244,957
Cash(4)
184,000
number of
equity
incentive
units(3)
18143
value of
equity
incentive
units(3)
73,763
Total
2013
2,502,720
(1) The highest paid member of Executive Management in 2013 was Tim Dyer (CEO from June 2013), who received total compensation of CHF680,340 comprising CHF438,577 of fixed cash
compensation including a termination indemnity of CHF303,662, CHF224,000 of variable cash compensation, 18,143 equity incentive units. The value of equity incentive units including accrued
social charges amounts to CHF73,763. Bharatt Chowrira (CEO until 31 May 2013) received total compensation of CHF369,669 comprising CHF196,592 of fixed cash compensation and a
termination indemnity of CHF173,077.
(2) Fixed cash compensation includes termination indemnity paid to the executive management.
(3) Equity incentive units relate to shares awarded for consulting services under the share purchase plan. (refer to note 15 of the consolidated financial statements)
(4) Post termination of their employment agreements, executive managers have been engaged under consulting contracts which include hourly and daily rates with a monthly cap.
Report of the statutory auditor to the General Meeting of Addex Therapeutics Ltd, Geneva
Report of the statutory auditor on the Compensation Report
We have audited pages 15-17 of the accompanying Compensation Report dated 30 April 2015 of Addex Therapeutics Ltd for the
year ended 31 December 2014.
Board of Directors’ responsibility
The Board of Directors is responsible for the preparation and overall fair presentation of the remuneration report in accordance with
Swiss law and the Ordinance against Excessive Compensation in Stock Exchange Listed Companies (Ordinance). The Board of
Directors is also responsible for designing the remuneration system and defining individual remuneration packages.
Auditor’s responsibility
Our responsibility is to express an opinion on the accompanying remuneration report. We conducted our audit in accordance with
Swiss Auditing Standards. Those standards require that we comply with ethical requirements and plan and perform the audit to
obtain reasonable assurance about whether the remuneration report complies with Swiss law and articles 14–16 of the Ordinance.
An audit involves performing procedures to obtain audit evidence on the disclosures made in the remuneration report with regard to
compensation, loans and credits in accordance with articles 14–16 of the Ordinance. The procedures selected depend on the
auditor’s judgment, including the assessment of the risks of material misstatements in the remuneration report, whether due to fraud
or error. This audit also includes evaluating the reasonableness of the methods applied to value components of remuneration, as
well as assessing the overall presentation of the remuneration report.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Opinion
In our opinion, the remuneration report of Addex Therapeutics Ltd for the year ended 31 December 2014 complies with Swiss law
and articles 14–16 of the Ordinance.
PricewaterhouseCoopers SA
Michael Foley
Audit expert
Auditor in charge
Geneva, 30 April 2015
Adrien Benoit
Audit expert
Page 17 of 52
Addex Therapeutics Annual Report 2014
Consolidated Financial Statements of Addex
Therapeutics Ltd as at December 31, 2014
Page 18 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements
Consolidated Balance Sheets
as at December 31, 2014 and December 31, 2013
Notes
31.12.2014
31.12.2013
ASSETS
Current assets
Cash and cash equivalents………………………………………………...
Other current assets………….………………………………………….….
Total current assets………………………………………………………..
Non-current assets
Intangible assets……………………………………………………………..
Property, plant and equipment……………………………………………..
Non-current financial assets………………………………………………..
Total non-current assets………………………………………………….
Total assets………………………………………….................................
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities
Payables and accruals………………………………………………………
Provision for other current liabilities……………………………………….
Deferred income……………………………………………………………..
Total current liabilities…………………………………………………….
Non-current liabilities
Post-employment benefits………………………………………………….
Total non-current liabilities……………………….................................
Shareholders’ equity
Share capital…………………………………………………………………
Share premium………………………………………………………………
Other reserves……………………………………………………………….
Accumulated deficit………………………………………………………….
Total shareholders’ equity………………………………………………..
7
8
9
10
11
12
13
21
14
1,979,609
159,389
2,138,998
13,216
44,677
1,802,331
1,860,224
2,913,396
987,612
3,901,008
52,584
179,524
1,746,535
1,978,643
3,999,222
5,879,651
1,494,595
—
14,397
1,508,992
144,536
144,536
2,353,400
9,841
—
2,363,241
490,435
490,435
9,984,888
260,020,862
6,127,826
(273,787,882)
2,345,694
9,843,247
259,689,854
5,505,898
(272,013,024)
3,025,975
Total liabilities and shareholders’ equity………………………………
3,999,222
5,879,651
The accompanying notes form an integral part of these consolidated financial statements.
Page 19 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements
Consolidated Statements of Income
for the years ended December 31, 2014 and 2013
Notes
2014
Amounts in Swiss francs
2013
Income
Research grants…………...………………………………….……………..
Other Income…………………………………………………………………
Total income………………………………………………………………...
Operating expenses
Research and development...……………………………………..............
General and administration….……………………………………………..
Total operating expenses………………………………………..............
Operating loss……………………………………………………..............
Finance income………………………………………………………………
Finance cost.....……………………………………....................................
Finance result, net…………………………………….............................
Net loss before tax…………………………………….............................
Income tax expense…………………..……...……………………………..
Net loss for the year...…………………………………………................
Basic and diluted loss per share for loss attributable to the
equity holders of the Company, expressed in Swiss francs……….
17
17
18
22
22
20
23
—
726,568
726,568
929,494
1,593,710
2,523,204
142,090
—
142,090
9,307,294
5,293,391
14,600,685
1,796,636
14,458,595
(1,586)
(20,192)
(21,778)
1,774,858
—
1,774,858
(4,134)
7,367
(3,233)
14,461,828
—
14,461,828
(0.18)
(1.60)
The accompanying notes form an integral part of these consolidated financial statements.
Page 20 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements
Consolidated Statements of Comprehensive Income
for the years ended December 31, 2014 and 2013
2014
2013
Amounts in Swiss francs
Net loss for the year……………………………………………………...……………
(1,774,858)
(14,461,828)
Other comprehensive gains and losses
Items that will never be reclassified to the statement of income:
Defined benefit plan actuarial gains / (losses)….………………………………..
372,054
(206,823)
Items that may or may not be classified subsequently to the statement
of income:
Currency translation differences…………………………………………………...
Other comprehensive gains / (losses) for the year, net of tax…………………
(25,866)
346,188
20,505
(186,318)
Total comprehensive loss for the year……………………………………………..
(1,428,670)
(14,648,146)
The accompanying notes form an integral part of these consolidated financial statements.
Page 21 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements
Consolidated Statements of Changes in Equity
for the years ended December 31, 2014 and 2013
Balance at
January 1,2013...................
8,633,531
257,715,600
5,517,741
(257,551,196)
14,315,676
Notes
Share
capital
Share
Premium
Other
reserves
Accumulated
deficit
Total
Amounts in Swiss francs
Net loss for
the year…….........................
Retirement benefit plan
actuarial loss….…................
Translation
differences…………………..
Other comprehensive
loss for the year……….…....
Total comprehensive
loss for the year……….…..
Issue of shares –
capital increase…................
Cost of share capital Issuance
capital Increase....................
Value of share-based
compensation…….…………
Net sale of treasury
shares……..…………………
Balance at January 1,
2014………….………….…..
Net loss for the
year………………………..…
Retirement benefit plan
actuarial gain……………..…
Translation
differences………………..…
Other comprehensive
loss for the year………….…
Total comprehensive
loss for the year………...…
Cost of share capital Issuance
capital increase……………..
Value of share-based
compensation.....…………...
Net sale of treasury
15
14
14
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
(14,461,828)
(14,461,828)
(206,823)
20,505
(186,318)
-
-
-
(206,823)
20,505
(186,318)
(186,318)
(14,461,828)
(14,648,146)
14
1,170,612
2,048,571
-
-
(167,105)
-
174,475
39,104
92,788
-
-
-
-
-
3,219,183
(167,105)
174,475
131,892
9,843,247
259,689,854
5,505,898
(272,013,024)
3,025,975
-
-
-
-
-
-
(1,774,858)
(1,774,858)
372,054
(25,866)
346,188
-
-
-
372,054
(25,866)
346,188
346,188
(1,774,858)
(1,428,670)
4,320
-
-
275,740
-
-
-
4,320
275,740
468,329
shares……….......................
14
141,641
326,688
-
Balance at
December 31, 2014………..
9,984,888
260,020,862
6,127,826
(273,787,882)
2,345,694
The accompanying notes form an integral part of these consolidated financial statements.
Page 22 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements
Consolidated Statements of Cash Flows
for the years ended December 31, 2014 and 2013
Notes
2013
2014
Amounts in Swiss francs
Cash flows from operating activities
Net loss for the year...…………………………………………...…………...
Adjustments for:
Depreciation and amortization……………………..............................
(Gain) / loss on disposal of fixed assets…………………………….…
Write off of non-current financial assets……………………………….
Impairment of non-current financial assets……………………………
Value of share-based compensation..…………………………………
Pension costs…………………………................................................
Finance result, net…………………….…………………………………
9/10
15
21
22
Changes in working capital:
Other current assets………………………………...............................
Deferred income, payables and accruals……...……………..............
Net cash used in operating activities….…………………………………
Cash flows from investing activities
Proceeds from sale of property, plant and equipment….….……………...
Interest received……………………………………………..………………..
Net cash from investing activities………………………...….……..……
Cash flows from financing activities
Proceeds from issue of shares – capital increase.……………..………….
Costs paid on issue of shares……………………………………………..…
Net proceeds from sales of treasury shares………………………………..
Net cash from financing activities………………...…............................
Decrease in cash and cash equivalents…………………………………
Cash and cash equivalents at beginning of the year...…………………....
Exchange loss on cash and cash equivalents……………………………..
Cash and cash equivalents at end of the year………..........................
22
14
7
7
(1,774,858)
(14,461,828)
110,135
(307,784)
—
—
275,740
26,155
(21,778)
744,061
(851,313)
(1,799,642)
371,864
1,586
373,450
—
4,320
468,329
472,649
662,549
45,012
822,648
995,569
174,475
(2,480,217)
3,233
758,938
(2,296,747)
(15,776,368)
251,933
4,134
256,067
3,219,183
(167,105)
131,892
3,183,970
(953,543)
(12,336,331)
2,913,396
19,756
15,256,708
(6,981)
1,979,609
2,913,396
The accompanying notes form an integral part of these consolidated financial statements.
Page 23 of 52
Addex Therapeutics Annual Report 2014│Consolidated Financial Statements
Notes to the Consolidated Financial Statements
for the years ended December 31, 2014 and 2013
(amounts in Swiss francs)
1. General information
Addex Therapeutics Ltd (the Company), formerly Addex Pharmaceuticals Ltd, and its subsidiaries (together, the Group) are a drug
discovery based pharmaceutical group focused on discovery, development and commercialization of small-molecule pharmaceutical
products for the treatment of human health. The Company is a Swiss stockholding corporation domiciled c/o Addex Pharma SA,
Chemin des Aulx 14, CH-1228 Plan-les-Ouates, Geneva, Switzerland and the parent company of Addex Pharma SA and Addex
Pharmaceuticals France SAS. Its registered shares are traded at the SIX, Swiss Exchange, under the ticker symbol ADXN.
To date, the Group has financed its cash requirements primarily from share issuances and out-licensing certain of its research and
development stage products. The Group is a development stage enterprise and is exposed to all the risks inherent in establish ing a
business. Inherent in the Group’s business are various risks and uncertainties, including the substantial uncertainty that current
projects will succeed. The Group’s success may depend in part upon its ability to (i) establish and maintain a strong patent position
and protection, (ii) enter into collaborations with partners in the pharmaceutical industry, (iii) acquire and retain key personnel, and (iv)
acquire additional capital to support its operations. The Board of Directors (Board) believes the Group will be able to meet all of its
obligations for a further 12 months as they fall due and, hence, the consolidated financial statements have been prepared on a going
concern basis. Further analysis is disclosed in note 4.1.
These consolidated financial statements have been approved by the Board of Directors on April 29, 2015. They are subject to
approval by the shareholders on June 11, 2015.
2. Summary of significant accounting policies
The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These
policies have been consistently applied to all the years presented, unless otherwise stated.
2.1 Basis of preparation
The consolidated financial statements of Addex Therapeutics Ltd have been prepared in accordance with International Financial
Reporting Standards (IFRS) and under the historical cost convention.
The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also
requires management to exercise its judgment in the process of applying the Group's accounting policies. The areas involving a
higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the consolidated financial
statements are disclosed in note 4.
Changes in accounting policies
The accounting policies used in the preparation of the consolidated financial statements are consistent with those used in the
consolidated financial statements for the year ended December 31, 2013, The following new standards, amendments to standards
and interpretations which are mandatory for the financial periods beginning on January 1, 2014 did not have any material impact on
the consolidated financial statements:
IAS 32 (Amendment), Offsetting Financial Assets and Financial Liabilities (effective from January 1, 2014);
IFRIC 21, Levies (effective from January 1, 2014);
IFRS 10, IFRS 12, IAS 27 (Amendments), Investment Entities (effective from January 1, 2014);
IAS 36 (Amendment), Recoverable Amount Disclosures for Non-Financial Assets (effective from January 1, 2014); and
IAS 39 (Amendment), Novation of Derivatives and Continuation of Hedge Accounting (effective from January 1, 2014).
The following new standards, amendments to standards and interpretations which have been published but are not yet effective and
have not been early adopted by the Group:
IAS 19 (Amendment), Employee Contributions (effective from July 1, 2014). The Group will apply this standard from January 1,
2015;
IFRS 14, Regulatory Deferral Accounts (effective January 1, 2016). The Group will apply this standard from January 1, 2016;
Page 24 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements│Notes
IFRS 15, Revenue from Contracts with Customers (effective from January 1, 2017). The Group will apply this standard from
January 1, 2017; and
IFRS 9, Financial Instruments (effective from January 1, 2018). The Group will apply this standard from January 1, 2018.
At this stage, the Group does not expect any significant impact from new or revised standards, with the exception of IFRS 15. The
Group will assess the potential impact of IFRS 15 in due course.
2.2 Consolidation
Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has
rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the
entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are de-consolidated from
the date that control ceases.
Inter-company transactions, balances and unrealized gains on transactions between Group companies are eliminated. Unrealized
losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of
subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group. The reporting date
of all Group companies is December 31.
2.3 Segment reporting
Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker.
The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating
segments, has been identified as the Chief Executive Officer.
2.4 Foreign currency transactions
Functional and presentation currency
Items included in the financial statements of each of the Group's entities are measured using the currency of the primary economic
environment in which the entity operates ("the functional currency"). The consolidated financial statements are presented in Swiss
francs, which is the Company's functional and presentation currency.
Transactions and balances
Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the
transactions or valuation where items are re-measured. Foreign exchange gains and losses resulting from the settlement of such
transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies
are recognized in the statement of income.
Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the statement of
income within ‘finance result, net’. All other foreign exchange gains and losses are presented in the statement of income within
‘operating expenses’.
Group companies
The results and financial position of the Group's subsidiary that has a functional currency different from the presentation currency are
translated into the presentation currency as follows:
assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet;
income and expenses for each statement of income are translated at the average exchange rate; and
all resulting exchange differences are recognized in other comprehensive income.
2.5 Property, plant and equipment
Property, plant and equipment are stated at historical cost less depreciation. Historical cost includes expenditure that is directly
attributable to the acquisition of the item. Subsequent costs are included in the asset's carrying amount or recognized as a separate
asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the
cost of the item can be measured reliably. All other repairs and maintenance are charged to the statement of income during the
financial period in which they are incurred. Depreciation is calculated using the straight-line method to allocate their cost to their
residual values over their estimated useful lives as follows:
Buildings
Leasehold improvements
Computer equipment
Laboratory equipment
25 years
(over life of lease)
3 years
4 years
Page 25 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements│Notes
Furniture and fixtures
Chemical library
5 years
5 years
The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at each balance sheet date. An asset's
carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated
recoverable amount (see note 2.7). Gains and losses on disposals are determined by comparing proceeds with carrying amount, and
are included in the statement of income.
2.6 Intangible assets
Acquired computer software licenses are capitalized on the basis of the costs incurred to acquire and bring to use the specific
software. These costs are amortized over their estimated useful lives (2 to 5 years) on a straight-line basis. Costs associated with
developing or maintaining computer software programs are recognized as an expense as incurred.
2.7 Impairment of non-financial assets
Assets that are subject to depreciation or amortization are reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset's
carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell and
value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately
identifiable cash flows (cash generating units). Prior impairment of non-financial assets other than goodwill is reviewed for possible
reversal at each reporting date.
2.8 Financial assets
The Group has one category of financial assets which is “loans and receivables”.
Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active
market. They arise when the Group provides money, goods or services directly to a debtor with no intention of trading the rec eivable.
They are included in current assets, except for maturities greater than 12 months after the balance sheet date, which are classified as
non-current assets. Loans and receivables are included in other current assets and non-current assets in the balance sheet (see note
8 and 11).
Loans and receivables are initially measured at fair value plus transaction costs that are directly attributable and subsequently
measured at amortized cost. Amortized cost is the amount at which the loan or receivable is measured at initial recognition minus
principal repayments, plus or minus the cumulative amortization using the effective interest method of any difference between that
initial amount and the maturity amount.
Loans and receivables are recognized on the trade-date, the date on which the Group commits to purchase or sell the asset. Loans
and receivables are derecognized when settled or when the rights to receive cash flows have expired.
A provision for impairment of loans and receivables is established when there is objective evidence that the Group will not be able to
collect all amounts due. The amount of impairment is the difference between the carrying amount and the present value of estimated
future cash flows discounted at the financial asset’s original effective interest rate, and is recognized in the statement of income. If, in
a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring
after the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was
recognized, the reversal of the previously recognized impairment loss is recognized in the statement of income.
2.9 Cash and cash equivalents
Cash and cash equivalents include cash on hand, deposits held at call with banks and other short-term highly liquid investments with
original maturities of three months or less.
2.10 Share capital
Common shares are classified as equity. Incremental costs directly attributable to the issue of new shares are shown as a deduction,
net of tax, from the proceeds.
Where any Group company purchases the Company's equity share capital (treasury shares), the consideration paid, including any
directly attributable incremental cost (net of income taxes) is deducted from equity attributable to the Company's equity holders until
the shares are cancelled, reissued or disposed of. Where such shares are subsequently sold or reissued, any consideration received,
Page 26 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements│Notes
net of any directly attributable incremental transaction costs and the related income tax effect, is included in equity attributable to the
Company's equity holders.
2.11 Equity instruments
Equity instruments issued by the Group are recorded at the fair value of the proceeds received, net of direct issuance costs.
2.12 Trade payables
Trade payables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method.
2.13 Grants
Grants are recognized at their fair value where there is reasonable assurance that the grant will be received and the Group will
comply with all attached conditions. Grants relating to costs are deferred and recognized as other income in the statement of income
over the period necessary to match them with the costs that they are intended to compensate.
2.14 Deferred income tax
Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets
and liabilities and their carrying amounts in the consolidated financial statements. However, if the deferred income tax arises from
initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects
neither accounting nor taxable profit or loss, it is not accounted for. Deferred income tax is determined using tax rates and laws that
have been enacted or substantively enacted by the balance sheet date and are expected to apply when the related deferred income
tax asset is realized or the deferred income tax liability is settled.
Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the
temporary differences can be utilized.
Deferred income tax is provided on temporary differences arising on investments in subsidiaries, except where the timing of the
reversal of the temporary differences is controlled by the Group and it is probable that the temporary difference will not reverse in the
foreseeable future.
2.15 Employee benefits
Pension obligations
Group companies operate various pension schemes. The schemes are generally funded through payments to insurance companies
or trustee-administered funds, determined by periodic actuarial calculations. The Group has defined benefit plans. A defined benefit
plan is a pension plan that defines an amount of pension benefit that an employee will receive on retirement, usually dependent on
one or more factors such as age, years of service and compensation. Actuarial gains and losses arising from experience adjustments
and changes in actuarial assumptions are recognized immediately in other comprehensive income and past-service costs are
recognized immediately in the statement of income.
The liability recognized in the balance sheet in respect of defined benefit pension plans is the defined benefit obligation at the balance
sheet date less the fair value of the plan assets. The defined benefit obligation is calculated annually by an independent actuary using
the projected unit credit method. The present value of the defined obligation is determined by discounting the estimated future cash
outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid,
and that have terms to maturity approximating to the terms of the related pension liability.
Share-based compensation
The Group operates an equity sharing certificates’ equity incentive plan, a share option plan and a share purchase plan: The fair
value of the services received in exchange for the grant or transfer of equity incentive units is recognized as an expense. The total
amount to be expensed over the vesting period is determined by reference to the fair value of the equity incentive unit granted or
transferred. The fair value of instruments granted includes any market performance conditions and excludes the impact of any service
and non-market performance vesting conditions. Service and non-market performance conditions are included in assumptions about
the number of equity incentive units that are expected to vest.
At each balance sheet date, the Group revises its estimates for the number of equity incentive units that are expected to vest. It
recognizes the impact of the revision to original estimates, if any, in the statement of income, with a corresponding adjustment to
equity.
Page 27 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements│Notes
The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share
premium when the equity incentive units are exercised.
2.16 Provisions
Provisions are recognized when the Group has a present legal or constructive obligation as a result of past events; it is probable that
an outflow of resources will be required to settle the obligation; and the amount has been reliably estimated. Provisions are measured
at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current
market assessments of the time value of money and the risks specific to the obligation.
2.17 Income recognition
Income, which currently relates primarily to collaborative arrangements, comprises the fair value for the sale of products and services,
net of value-added tax, rebates and discounts. Income from the sale of products is recognized when the product has been delivered
and accepted by the customer and collectability of the receivable is reasonably assured. Income from the rendering of services is
recognized in the accounting period in which the services are rendered, by reference to completion of the specific transaction
assessed on the basis of the actual service provided as a proportion of the total service to be provided. Income from collaborative
arrangements may include the receipt of non-refundable license fees, milestone payments, and research and development
payments. When the Group has continuing performance obligations under the terms of the arrangements, non-refundable fees and
payments are recognized as income by reference to the completion of the performance obligation and the economic substance of the
agreement.
2.18 Finance income and expense
Interest received and interest paid are classified in the statement of cash flows as interest received under investing activities and
finance expense under financing activities, respectively.
2.19 Leases
Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating
leases. Payments made under operating leases (net of any incentives received from the lessor) are charged to the statement of
income on a straight-line basis over the period of the lease.
2.20 Research and development
it is technically feasible to complete the intangible asset so that it will be available for use or sale;
Research and development costs are expensed as incurred. Costs incurred on development projects are recognized as intangible
assets when the following criteria are fulfilled:
management intends to complete the intangible asset and use or sell it;
there is an ability to use or sell the intangible asset;
it can be demonstrated how the intangible asset will generate probable future economic benefits;
adequate technical, financial and other resources to complete the development and to use or sell the intangible asset are
available; and
the expenditure attributable to the intangible asset during its development can be reliably measured.
In the opinion of management, due to uncertainties inherent in the development of the Group's products, the criteria for development
costs to be recognized as an asset, as prescribed by IAS 38, “Intangible Assets”, are not met.
Property, plant and equipment used for research and development purposes are capitalized and depreciated in accordance with the
Group's property, plant and equipment policy (see note 2.5).
Page 28 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements│Notes
3. Financial risk management
3.1 Financial risk factors
The Group's activities expose it to a variety of financial risks: market risk, credit risk, liquidity risk and capital risk. The Group's overall
risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the
Group's financial performance. Risk management is carried out by the Group's finance department (Group Finance) under the
policies approved by the Board. Group Finance identifies, evaluates and in some instances economically hedges financial risks in
close co-operation with the Group's operating units. The Board provides written principles for overall risk management, as well as
written policies covering specific areas, such as foreign exchange risk, interest-rate risk, use of derivative financial instruments and
non-derivative financial instruments, credit risk, and investing excess liquidity.
Market risk
The Group operates internationally and is exposed to foreign exchange risk arising from various exposures, primarily with respect to
the Euro, US dollar and UK pound. Foreign exchange risk arises from future commercial transactions, recognized assets and
liabilities and net investments in foreign operations. To manage foreign exchange risk Group Finance maintains foreign currency cash
balances to cover anticipated future requirements. The Group's risk management policy is to economically hedge 50% to 100% of
anticipated transactions in each major currency for the subsequent 12 months. The Group has a subsidiary in France, whose net
assets are exposed to foreign currency translation risk. In 2014, a 10% increase or decrease in the EUR/CHF exchange rate would
have resulted in a CHF10,540 (2013: CHF98,866) increase or decrease in net income and shareholders’ equity as at December 31,
2014, a 10% increase or decrease in the GBP/CHF exchange rate would have resulted in a CHF33,193 (2013: CHF120,624)
increase or decrease in net income and shareholders’ equity as at December 31, 2014 and a 10% increase or decrease in the
USD/CHF exchange rate would have resulted in a CHF55,777 (2012: CHF259,363) increase or decrease in net income and
shareholders’ equity as at December 31, 2014. Movements in other currencies would not have had a material impact. The Group is
not exposed to equity price risk or commodity price risk as it does not invest in these classes of investment. The Group's income and
operating cash flows are substantially independent of changes in market interest rates. Therefore the Group has no significant
interest rate risk exposure.
Credit risk
Credit risk is managed on a Group basis. Credit risk arises from cash and cash equivalents and deposits with banks, as well as credit
exposures to collaboration partners. The Group has a limited number of collaboration partners and consequently has a significant
concentration of credit risk. The Group has policies in place to ensure that credit exposure is kept to a minimum and significant
concentrations of credit risk are only granted for short periods of time to high credit quality partners. The Group's policy is to invest
funds in low risk investments including interest bearing deposits. For banks and financial institutions, only independently rated parties
with a minimum rating of “A” are accepted (see note 7).
Liquidity risk
The Group's principal source of liquidity is its cash reserves which are obtained through the sale of new shares and to a lesser extent
the sale of its research and development stage products. Group Finance monitors rolling forecasts of the Group’s liquidity
requirements to ensure it has sufficient cash to meet operational needs. The ability of the Group to maintain adequate cash reserves
to sustain its activities in the medium term is highly dependent on the Group's ability to raise further funds from the licensing of its
development stage products and the sale of new shares. Consequently, the Group is exposed to significant liquidity risk (see note
4.1).
3.2 Capital risk management
The Company and its subsidiaries are subject to capital maintenance requirements under Swiss and French law, respectively. To
ensure that statutory capital requirements are met, the Group monitors capital periodically, at the entity level, on an interim basis as
well as annually. From time to time the Group may take appropriate measures or propose capital increases to ensure the necess ary
capital remains intact.
3.3 Fair value estimation
The nominal value less estimated credit adjustments of trade receivables and payables are assumed to approximate to their fair
values. The fair value of other financial assets and liabilities for disclosure purposes is estimated by discounting the future contractual
cash flows at the current market interest rate that is available to the Group for similar financial instruments.
4. Critical accounting estimates and judgments
Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations
of future events that are believed to be reasonable under the circumstances.
Page 29 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements│Notes
4.1 Critical accounting estimates and assumptions
The Group makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom
equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the
carrying amounts of assets and liabilities or may have had a significant impact on the reported results are disclosed below:
Uncertainties and ability to continue operations
As discussed in note 1 under “general information”, The Board of Directors (Board) believes the Group will be able to meet all of its
obligations for a further 12 months as they fall due and, hence, the consolidated financial statements have been prepared on a going
concern basis. The Group is currently engaged in a number of activities to ensure that it can continue its operations, including
monetizing its assets, raising additional capital and pursuing strategic alternatives. The outcome of these activities is inherently
uncertain and had the Board assessed differently the ability of the Group to execute on its current financial plans and the ability of the
Group to meet all of its obligations for a further 12 months then the Group would have presented the consolidated financial
statements on a liquidation basis. Had the consolidated financial statements been prepared on a liquidation basis then certain
commitments and contingencies (refer to details of operating lease commitments in note 24) would have been recorded on the
balance sheet and certain assets would have been written down to their recoverable amounts (refer to other current assets in note 8
and non-current financial assets in note 11).
Income taxes
As disclosed in note 20 the Group has significant Swiss tax losses. These tax losses represent potential value to the Group to the
extent that the Group is able to create taxable profits within 7 years of the end of the year in which the losses arose. The Group has
not recorded any deferred tax assets in relation to these tax losses. The key factors which have influenced management in arriving at
this evaluation are the fact that the Group has not yet a history of making profits and product development remains at an early stage.
Should management's assessment of the likelihood of future taxable profits change, a deferred tax asset will be recorded.
Commitments and contingencies
In assessing the need for provisions for legal cases, estimates and judgements are made by the Group with support of external legal
advisors and other technical experts in order to determine the probability, timing and amounts involved. The Group is currently in
dispute with the French tax authorities and in this regard an amount of EUR1,202,610 (CHF1,446,259) has been deposited in an
escrow account until the outcome of the pending legal proceedings, that could take up to 7 years (see note 11). Based on support
provided by French tax experts and lawyers, the management assessed the chance of the claim of the French tax authorities being
successful as remote and therefore no provision has been made in the consolidated financial statements. Had the management
assessed the risk of a cash outflow as probable, the Group would have provided for the amount and this would have resulted in an
additional charge to the statement of income of CHF1,446,259.
Share-based compensation
The Group recognizes an expense for share-based compensation based on the valuation of equity incentive units using binomial and
Black-Scholes valuation models. A number of assumptions are made in these models. Should the assumptions and estimates
underlying the fair value of these instruments vary significantly from management's estimates, then the share-based compensation
expense would be materially different from the amounts recognized. Had these assumptions been modified within their feasible
ranges and the Group calculated the share-based compensation based on the higher and lower values of these ranges, share-based
compensation expense in 2014 would have been CHF241,528 or CHF309,247, respectively (2013: CHF140,054 or CHF193,580,
respectively). This is compared to the amount recognized as an expense in 2014 of CHF275,740 (2013: CHF174,475). Additional
information is disclosed in note 15.
Pension obligations
The present value of the pension obligations depends on a number of factors that are determined on an actuarial basis using a
number of assumptions. The assumptions used in determining the net cost for pensions include the discount rate. Any changes in
these assumptions will impact the carrying amount of pension obligations. The Group determines the appropriate discount rate at the
end of each year. This is the interest rate that should be used to determine the present value of estimated future cash outflows
expected to be required to settle the pension obligations. In determining the appropriate discount rate, the Group considers the
interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have
terms to maturity approximating the terms of the related pension liability. Other key assumptions for pension obligations are based in
part on current market conditions. Additional information is disclosed in note 21.
Loans to employees
In connection with the granting of equity sharing certificates (ESCs), the Group has made loans to its employees to finance the tax
and social charges consequences of the grant of ESCs. The loans are only repayable if capital gains are realised from the exercise of
the subscription rights attached to the ESCs. ESCs’ subscription rights are exercisable, subject to vesting, until their expiry date, at
their subscription price only if the underlying share price exceeds a predefined floor price. As at December 31, the total of loans that
are not related to forfeited or expired subscription rights amount to CHF764,800 (2013: CHF764,800). At December 31, 2014 and
Page 30 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements│Notes
2013, no amount of these loans was assessed as recoverable within 12 months and no amount was assessed as recoverable in
more than 1 year. The loans were tested for impairment based on the historic volatility, the closing share price at December 31, 2013
of CHF2.32 and expected forfeiture and expiry rates. Had the Group made different assumptions regarding the recoverability of these
loans, then their carrying value would have changed accordingly. In 2014, this would have resulted in an income of between CHF0
and CHF764,800 compared to the amount recognized as an expense in 2013 of CHF764,800.
4.2 Critical judgments in applying the accounting policies
Development supplies
At December 31, 2014, the Group owns development supplies that have been expensed in the statement of income. These amounts
have not been recognized on the balance sheet as an asset since they are to be used in pre-clinical and clinical trials of specific
products that have not demonstrated technical feasibility.
5. Segment information
5.1 Reportable segments
The Group operates in one segment, which is the business of developing drugs to improve human health.
5.2 Entity wide information
In 2013 and 2014, no income was received from collaborative arrangements or the sale of license rights to pharmaceutical
companies. Refer to note 17 for other income and research grants received.
The geographical analysis of assets is as follows:
Switzerland…………….………………………........
Current………………………………………………...
Non-current…………………………………………...
Europe…………………………………...……….....
Current………………………………………………...
Non-current…………………………………………...
Total assets……………………..………………......
The geographical analysis of operating expenses is as follows:
Switzerland…………….………………………........
Europe…………………………………...……….....
Total operating expenses (note 18)……………….
There was no capital expenditure in 2014 and 2013.
6. Consolidated entities
December 31, 2014
December 31, 2013
2,531,046
2,117,080
413,966
1,468,176
21,917
1,446,259
3,999,222
4,356,572
3,978,826
377,746
1,523,079
154,290
1,368,789
5,879,651
2014
2013
1,754,526
20,332
1,774,858
14,609,548
(8,863)
14,600,685
The consolidated financial statements include the accounts of Addex Therapeutics Ltd and its 100% owned subsidiaries, Addex
Pharma SA and Addex Pharmaceuticals France SAS.
7. Cash and cash equivalents
Cash at bank and on hand……………………...........
Total cash and cash equivalents………………......
1,979,609
1,979,609
2,913,396
2,913,396
December 31, 2014
December 31, 2013
In 2014, the effective interest rate on cash and cash equivalents was 0.0% (2013: 0.00%).
Page 31 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements│Notes
Credit quality of cash and cash equivalents
The table below shows the cash and cash equivalents by credit rating of the major counterparties:
External credit rating of counterparty
December 31, 2014
December 31, 2013
P-1 / A-1………...………………………………..…
Cash on hand………………………………………..
Total cash and cash equivalents………………......
1,977,922
1,687
1,979,609
2,910,405
2,991
2,913,396
External credit ratings of counterparties were obtained from Moody’s (P-1) or Standard & Poor’s (A-1), respectively.
8. Other current assets
Receivables……………………………………….……
Prepayments…………………………………………...
Total other current assets……………………..…...
91,507
67,882
159,389
811,549
176,063
987,612
December 31, 2014
December 31, 2013
As at December 31, 2014 and 2013, there are no loans to employees or related parties in current assets.
Movements in the provision for impairment of receivables were as follows:
At January 1……………………………………………..
Provisions for receivables impairments……………….
Receivables written off during the year as
uncollectible……………………………………………...
Unused amounts reversed …………………………….
At December 31………………………………………...
2014
—
93,771
—
—
93,771
9. Intangible assets
At January 1, 2013
Cost…………………………………………………………………………………………
Accumulated amortization………………………………………………………………..
Net book value…………………………………………………………………………….
Year ended December 31, 2013
Opening net book amount……………………………………………………………….
Amortization charge………………………………………………………………………
Closing net book amount……………………………………………………………...
At December 31, 2013
Cost…………………………………………………………………………………………
Accumulated amortization…………………………………………………………….....
Net book value…………………………………………………………………………….
Year ended December 31, 2014
Opening net book amount……………………………………………………………….
Disposals
Amortization charge………………………………………………………………………
Closing net book amount……………………………………………………………...
At December 31, 2014
Cost…………………………………………………………………………………………
Accumulated amortization…………………………………………………………….....
Net book value………...…………………………………………………………………
Computer software
licenses
870,184
(772,588)
97,596
97,596
(45,012)
52,584
870,184
(817,600)
52,584
52,584
(752)
(38,616)
13,216
108,955
(95,739)
13,216
The Group recorded an amortization charge in 2014 of CHF33,824 (2013: CHF34,873) as part of research and development
expenses and CHF4,792 (2013: CHF10,139) as part of general and administration expenses.
Page 32 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements│Notes
10. Property, plant and equipment
At January 1, 2013
Cost…………………………....
Accumulated depreciation…..
Net book value.......................
Buildings
32,698
(10,788)
21,910
Year ended December 31, 2013
Opening net book amount......
Disposals……………………...
Impairment
Depreciation charge………….
Closing net book amount….
At December 31, 2013
Cost………………………........
Disposal……………………….
Impairment…………………….
Accumulated depreciation..…
Net book value………………..
Year ended December 31, 2014
Opening net book amount......
Disposals……………………...
Depreciation charge………….
Closing net book amount….
At December 31, 2014
Cost………………………........
Accumulated depreciation ….
Net book value………….…..
21,910
-
-
(1,486)
20,424
32,698
-
-
(12,274)
20,424
20,424
(20,424)
-
-
12,274
(12,274)
-
Leasehold
improvements
8,101,158
(6,623,504)
1,477,654
1,477,654
-
(995,569)
(482,085)
-
-
8,101,158
-
(995,569)
(7,105,589)
-
-
-
-
-
-
-
-
Equipment
10,676,481
(10,334,957)
341,524
Furniture
& fixtures
Chemical
library
1,296,875
(1,211,322)
85,553
1,204,427
(1,041,494)
162,933
341,524
(251,933)
-
(46,766)
42,825-
10,424,548
(251,933)
-
(10,381,723)
42,825
42,825
(26,939)
(14,677)
1,209
3,123,337
(3,122,128)
1,209
85,553
-
-
(61,172)
24,381-
1,296,875
-
-
(1,272,494)
24,381
24,381
(15,965)
(6,330)
2,086
66,713
(64,627)
2,086
162,933
-
-
(71,039)
91,894-
1,204,427
-
-
(1,112,533)
91,894
91,894
-
(50,512)
41,382
Total
21,311,639
(19,222,065)
2,089,574
2,089,574
(251,933)
(995,569)
(662,548)
179,524
21,059,706
(251,933)
(995,569)
(19,884,613)
179,524
179,524
(63,328)
(71,519)
44,677
1,204,427
(1,163,045)
41,382
4,406,751
(4,362,074)
44,677
The Group recorded a depreciation charge in 2014 of CHF67,445 (2013: CHF631,963) as part of research and development
expenses and CHF 4,074 (2013: CHF30,585) as part of general and administration expenses.
11. Non-current financial assets
Security rental deposit...…………………………......
Other deposits……………………………………..….
Total non-current financial assets…………..……
356,072
1,446,259
1,802,331
386,941
1,359,594
1,746,535
December 31, 2014
December 31, 2013
As at December 31, 2014, the Company has recorded an amount of EUR1,202,610 (CHF1,446,259) in other non-current financial
assets for an escrow account related to claims from the French tax authorities that are in dispute (see note 4.1). As at December 31,
2013, this amount was EUR 1,108,967 (CHF 1,359,593).
12. Payables and accruals
Trade payables…………………………...…………..
Social security and other taxes……………………...
Accrued expenses…………………………………....
Total payables and accruals……………………….
All payables mature within 3 months.
December 31, 2014
December 31, 2013
647,304
11,500
835.791
1,494,595
605,803
30,022
1,717,575
2,353,400
Page 33 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements│Notes
13. Provisions for other liabilities
At January 1, 2013……………………………………
Provision linked to restructuring charges:
Amount utilized during the period…………………..
Exchange differences………………………………..
At December 31, 2013………………………….......
Amount utilized during the period…………………..
At December 31, 2014………………………….......
Current
65,1913
(56,357)
1,005
9,841
(9,841)
—
Amounts utilized in 2014 and 2013 relate to the termination of lease contracts.
14. Share capital and share premium
Balance at January 1, 2013……………………......
Issue of shares - capital increase…..…...................
Sales of treasury shares……………………………..
Balance at December 31, 2013…………………....
Sale of treasury shares………………......................
Balance at December 31, 2014…………………….
Common
shares
9,002,964
1,170,612
—
10,173,576
—
10,173,576
Number of shares
Treasury
shares
(369,433)
—
39,104
(330,329)
141,641
(188,688)
Total
8,633,531
1,170,612
39,104
9,843,247
141,641
9,984,888
At December 31, 2014, the total outstanding share capital is CHF10,173,576 (December 31, 2013: CHF10,173,576), consisting of
10,173,576 shares (December 31, 2013: 10,173,576). All shares have a nominal value of CHF1 and are fully paid.
During 2014 the Group sold 141,641 treasury shares for gross proceeds of CHF468,329.
On August 9, 2013, the Group issued 1,170,612 new shares in a private placement for CHF2.75 per share. The gross proceeds of
CHF3,219,183 have been recorded in equity net of directly related share issuance costs of CHF167,104. CHF4320 of accrued share
issuance costs have not been used and have therefore been released in 2014.
15. Share-based compensation
The total share-based compensation expense recognized in the statement of income for equity incentive units granted to directors,
executives, employees and consultants has been recorded under the following headings:
Research and development………………...…………
General and administration…….……………………...
Total share-based compensation..…………………
987
274,753
275,740
154,739
19,736
174,475
2014
2013
Analysis of share-based compensation by equity incentive plan is detailed as follows:
Equity sharing certificate plan……………...…………
Share purchase plan……..…….……………………...
Share option plans……………………………………..
Total share-based compensation..…………………
132,758
16,498
126,484
275,740
164,309
9,790
386
174,475
2014
2013
Page 34 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements│Notes
Equity Sharing Certificate Equity Incentive Plan
On June 1, 2010, the Company established an equity incentive plan based on equity sharing certificates (ESCs) to provide incentives
to directors, executives, employees and consultants of the Group. Each ESC provides the holder (i) a right to subscribe for 1,000
shares in the Company, and (ii) a right to liquidation proceeds equivalent to that of shareholders. All rights of the ESCs expire after a
5 year period from date of grant with the ownership of the ESCs reverting to the Group. ESCs granted are subject to certain vesting
conditions which are defined in each grant agreement. The holder of vested ESCs has the right to subscribe to shares at the
subscription price if the underlying share price has reached the floor price. The floor and subscription price are defined by the Board
of Directors. In the event of a change in control, all ESCs automatically vest. The Group has no legal or constructive obligation to
repurchase or settle ESCs in cash.
On June 1, 2010, the Group granted 767 ESCs at a floor price of CHF15.00 per share and a subscription price of CHF7.50 per share.
In accepting the grant of ESCs, the holders automatically forfeited all previously granted share options and consequently the ESC
grant has been considered to be a replacement of the respective cancelled share options, under IFRS 2. At December 31, 2014, of
the 767 ESCs granted in 2010, 259,939 subscription rights have been forfeited or expired. Of the remaining 507,061 subscription
rights, 348,061 are vested and expire in 2015, 159,000 have been reprised at a floor price of CHF2.30 and a subscription price of
CHF1.00 per share. At December 31, 2014, 53,000 are vested, 106,000 continue to vest over 4 years from their reprising date and
expire in 2019.
On January 1, 2011 and July 1, 2011, the Group granted 6 ESCs, respectively at a floor price of CHF14.00 per share and a
subscription price of CHF7.00 per share. On August 15, 2011, the Group granted 320 ESCs at a floor price of CHF15.00 per share
and a subscription price of CHF7.50 per share. On November 15, 2011, the Group granted 366 ESCs at a floor price of CHF8.00 per
share and a subscription price of CHF4.00 per share. Of the 366 ESCs granted on November 15, 2011, 11 were granted to holders of
share options. In accepting the grant of ESCs, the option holders automatically forfeit all previously granted share options and
consequently the grant of these 11 ESC have been considered to be a replacement of the respective cancelled share options, under
IFRS 2. At December 31, 2014, of the 692 ESCs granted in 2011, 373,551 subscription rights have been forfeited or expired. Of the
remaining 318,449 subscription rights, 210,643 are vested and 11,115 continue to vest over 4 years from their original grant date,
and expire in 2016. As of June 30, 2014, 55,000 subscription rights have been reprised at a floor price of CHF2.30 and a subscription
price of CHF1.00 per share and are fully vested. As of December 31, 2014, 41,691 subscription rights has been reprised at a floor
price of CHF2.30 and a subscription price of CHF1.00 per shares, vesting over 4 years and expire in 2019.
On April 1, 2012, the Group granted 1 ESC at a floor price of CHF13.00 per share and a subscription price of CHF6.50 per share. On
May 3, 2012, the Group granted 50 ESCs at a floor price of CHF13.00 per share and a subscription price of CHF6.50 per share. On
June 29, 2012, the Group granted 90 ESCs at a floor price of CHF13.00 per share and a subscription price of CHF6.50 per share.
On October 1, 2012, the Group granted 5 ESCs at a floor price of CHF13.00 per share and a subscription price of CHF6.50 per
share. At December 31, 2014, of the 146 ESCs granted in 2012, 58,500 subscription rights have been forfeited or expired, 78,500
subscription rights are fully vested and expire in 2017, and 10,000 subscription rights have been reprised at a floor price of CHF2.30
and a subscription price of CHF1.00 per share with a vesting overs 4 years and expire in 2019.
On January 1, 2013, the Group granted 8 ESCs at a floor price of CHF14.00 per share and a subscription price of CHF7.00 per
share. The ESCs granted are subject to a 4 year quarterly vesting period, with a 1 year cliff period. On March 11, 2013, the Group
granted 83 ESCs at a floor price of CHF10.00 per share and a subscription price of CHF5.00 per share. At December 31, 2014, of the
91 ESCs granted in 2013, 62,667 subscription rights have been forfeited or expired. Of the remaining 10,333 subscription rights,
5,833 are vested and 4,500 continue to vest over 4 years from their original grant date, and expire in 2018. As of December 31, 2014,
18,000 subscription rights have been reprised at a floor price of CHF2.30 and a subscription price of subscription price of CHF1.00
per share, vesting over 4 years and expire in 2019.
Movements in the number of subscription rights attached to the ESCs outstanding are as follows:
At January 1………………………………………………………..
Granted……………………………………………………………..
Forfeited……………………………………………………...........
Expired……………………………………………………………..
Exercised…………………………………………………………..
At December 31…………………………………………….........
2014
942,343
-
-
-
-
942,343
2013
1,295,039
91,000
(418,858)
(24,838)
-
942,343
At December 31, 2014, of the outstanding 942,343 subscription rights (2013: 942,343) attached to the ESCs, 751,037 (December 31,
2013: 852,142) were exercisable.
Page 35 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements│Notes
The outstanding subscription rights as at December 31, 2014 and 2013 have the following expiry dates, subscription prices and floor
prices:
At December 31, 2014
Subscription prices / floor prices (CHF)
Expiry date
1.00 / 2.30 4.00 / 8.00 5.00 / 10.00 6.50 / 13.00 7.00 / 14.00 7.50 / 15.00
Total
2015……………………………...
2016……………………………...
-
-
-
154,476
2017……………………………...
108,000
2018……………………………...
-
2019……………………………...
144,973
-
-
-
-
-
-
13,000
-
-
-
83,500
-
-
5,250
2,250
-
2,333
-
361,061
67,500
-
-
-
366,311
224,226
191,500
15,333
144,973
Total subscription rights…….
252,973
154,476
13,000
83,500
9,833
428,561
942,343
At December 31, 2013
Subscription prices / floor prices (CHF)
Expiry date
4.00 / 8.00 5.00 / 10.00 6.50 / 13.00 7.00 / 14.00 7.50 / 15.00
Total
2015…………………………......
2016……………………………...
2017……………………………...
2018……………………………...
-
243,449
-
-
Total subscription rights…….
243,449
-
-
-
26,000
26,000
-
-
88,500
-
88,500
-
507,061
7,500
67,500
507,061
318,449
88,500
28,333
-
-
574,561
942,343
-
2,333
9,833
The weighted average fair value of ESC subscription rights granted during 2013, determined using a customized binomial valuation
model, was CHF1.80. There were no grants of ESCs during 2014. During 2014, 283,691 ESC subscription rights were reprised at a
subscription price of CHF1 and floor price of CHF2.30. The weighted average fair value of the reprising of each ESC subscription
right was determinate using the Black-Scholes valuation model at CHF1.18.
The significant inputs to the models were:
Weighted average share price / share price at the grant date………….…
Weighted average subscription price / subscription price per share….….
Weighted average floor price / floor price per share……………………….
Weighted average volatility / volatility………………………………………..
Dividend yield………………………………………………………….............
Weighted average annual risk free rate / annual risk-free rate……………
Share option plans
2014
2013
CHF2.40
CHF1.00
CHF2.30
50.00%
—
0.13%
CHF7.41
CHF5.00
CHF10.00
41.72%
—
0.07%
The Company established share option plans in 2007, 2008 and 2014 to provide incentives to directors, executives, employees and
consultants of the Group. As a result of the granting of ESCs in 2011 and 2010, 2,500 and 226,000 options, respectively, were
forfeited. For accounting purposes the cancellation of these share options was treated as a modification under IFRS 2 and the portion
of the original fair value that was unrecognized at the date of forfeiture is being recognized over the original vesting period.
On July 1, 2014, the Group granted 400,000 options, 300,000 options at an exercise price of CHF 2 and 100,000 options at an
exercise price of CHF 5. On December 31, 2014 the Group granted 164,501 options at an exercise price of CHF 2. Options vest over
4 years and expired in 2019.
Page 36 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements│Notes
Movements in the number of options outstanding are as follows:
At January 1…………………………………………………….
Granted………………………...………………………………..
At December 31……………………………..........................
-
564,501
564,501
At December 31, 2014, of the outstanding 564,501 share options (2013: 0), 50,000 (December 31, 2013: 0) were exercisable.
The outstanding share options as at December 31, 2014 have the following expiry dates:
At December 31, 2014
Expiry date
2019……………………......
Total…………………….....
2.00
464,501
464,501
Exercises prices (CHF)
5.00
100,000
100,000
Total
564,501
564,501
The weighted average fair value of share options granted during 2014 determined using a Black-Scholes model was CHF0.90. The
significant inputs to the model were:
Weighted average share price per share at the grant date…………..
Weighted average strike price per share……………………...……….
Weighted average volatility / volatility…………………………………..
Dividend yield……………………………………………………………..
Weighted average annual risk free rate / annual risk-free rate………
Share purchase plan
2014
CHF2.37
CHF2.00
50%
—
0.13%
The Group established a share purchase plan under which services are settled for shares. Under the plan directors, executives,
employees and consultants may receive fully paid ordinary shares from the Group’s treasury share reserve for services rendered.
During 2014, 41,651 shares were transferred to settle CHF112,498 of consulting fees.
16. License and collaboration agreements
Janssen Pharmaceuticals Inc. (formerly Ortho-McNeil-Janssen Pharmaceuticals Inc).
On December 31, 2004, the Group entered into a research collaboration and license agreement with Janssen Pharmaceuticals Inc.
(JPI). In accordance with this agreement, JPI has acquired an exclusive worldwide license to develop mGluR2PAM compounds for
the treatment of human health. The Group is eligible for future payments contingent on the products from the research achieving
certain development milestones. The Group is also eligible for low double digit royalties on net sales. During 2014, the Group
recognized CHF726,568 of other income following amendment of the agreement. Under the amendment certain jointly owned patents
have been assigned to JPI and all past patent costs paid by the Group have been reimbursed. No income has been recognized under
this agreement in 2013.
17. Income
During 2014, the Group recognized CHF726,568 of other income from Janssen Pharmaceuticals Inc., following the amendment of the
license and collaboration agreement (see note 16). During 2013, the Group recognized CHF142,090 of research grants from The
Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant was received in instalments and recognized as other income
over the period necessary to match it against the specific research costs it was intended to compensate. In 2014, CHF14,397 has
been received from the MJFF and has been recorded in deferred income as it relates to activities planned for 2015
Page 37 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements│Notes
18. Operating expenses by nature
Staff costs (note 19)…………………………………....
Depreciation and amortization………………………...
External research and development costs…………...
Laboratory consumables…………………...………….
Patent costs……………………………………………..
Professional fees……………………………………….
Operating leases………………………………………..
Other operating expenses……………………………...
Total operating expenses…………………………….
2014
2013
355,446
110,135
258,058
85,404
373,155
1,111,469
81,004
148,433
2,523,204
5,105,762
662,549
2,220,131
91,760
1,021,650
1,266,672
1,362,961
2,869,200
14,600,685
Operating lease contracts are renewable on normal business terms and provide for annual rent increases based on the Swiss
consumer price index.
19. Staff costs
Wages and salaries.…………………………………..…
Social charges and insurances….…………...………...
Value of share-based services (note 15)………......….
Pension costs – defined benefit plans (note 21)….…..
Other employee costs……………………………..…….
Total staff cost (note 18)………………...…….……...
20. Taxes
Loss before tax……………………………………........
Tax calculated at a tax rate of 7.8% (2012: 7.8%)…..
Effect of different tax rates in other countries………..
Expenses charged against equity……………………..
Expenses not deductible for tax purposes……………
Tax losses not recognized as deferred tax assets.....
Income tax expense…………………………….……..
2014
2013
274,460
33,204
2,081
52,904
(7,203)
355,446
5,369,597
515,479
171,832
(2,121,972)
1,170,826
5,105,762
December 31, 2014
December 31, 2013
1,774,858
138,439
(1,573)
—
(21,507)
(115,778)
—
14,461,828
1,128,023
679
13,034
(13,609)
(1,128,127)
—
The Group is subject to Swiss income taxes and has a tax loss carry forward of CHF172,392,982 as of December 31, 2014 (2013:
CHF206,111,236), of which CHF156,156,296 (2013: CHF164,630,581) expire within the next five years and CHF16,236,686 (2013:
CHF41,480,655) will expire between five and seven years. Tax losses of CHF35,085,765 expired in 2014 (2013: CHF17,094,276).
21. Retirement benefit obligations
Apart from the social security plans fixed by the law, the Group sponsors independent pension plans. All employees are covered by
these plans, which are defined benefit plans. Retirement benefits are based on contributions, computed as a percentage of salary,
adjusted for the age of the employee and shared approximately 46%/54% by employee and employer. In addition to retirement
benefits, the plans provide death and long-term disability benefits to its employees. Liabilities and assets are revised every year by an
independent actuary. In accordance with IAS 19 (revised), plan assets have been estimated at fair market values and liabilities have
been calculated according to the "projected unit credit" method.
The Group recorded a pension benefit charge in 2014 of CHF 92,128 (2013: charge of CHF2,121,972) as part of staff costs.
Page 38 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements│Notes
Pension benefits
The amounts recognized in the balance sheet are determined as follows:
Defined benefit obligation………..…………...……...
Fair value of plan assets…………………….……….
Funded status………………………………..………..
2014
2013
(2,057,079)
1,912,543
(144,536)
(1,739,890)
1,249,455
(490,435)
The amounts recognized in the statements of income are as follows:
Current service cost……………….…………………
Interest cost………………………..………...……….
Interest income…………………..…………………...
Curtailment gain…..………………………………….
Company pension income / (cost) (note 19)……
2014
2013
(134,522)
(44,273)
33,572
—
(145,223)
(493,481)
(68,534)
53,417
2,332,491
1,823,893
The movement in the defined benefit obligations at the beginning of the year is as follows:
Defined benefit obligation at beginning of year.....….
Service cost…………………………………....…....….
Interest cost………………………………...……….….
Change in financial assumptions
Experience Adjustments……………..………….……
Increase in disability obligation…………….…….……
Curtailment………………………………………..…….
Defined benefit obligations at end of year………..
2014
2013
(1,739,890)
(134,522)
(44,273)
(366,589)
(504,983),
—
(2,057,079)
(9,277,580)
(493,481)
(68,534)
(170,230)
434,710
7,835,225
(1,739,890)
The movements in the fair value of plan assets during the year are as follows:
Fair value of plan assets at beginning of year……....
Interest income………………………………………....
Employees’ contributions…………………………......
Company contribution…………………………………
Plan assets gains / (losses)…………………………..
Disability insurance………………………………
Curtailment……………………………………………..
Fair value of plan assets at end of year…………..
The principal actuarial assumptions used were as follows:
2014
2013
1,249,455
33,572
53,095
65,973
5,465
504,983
—
1,912,543
6,513,751
53,417
298,079
358,245
(36,593)
(434,710)
(5,502,734)
1,249,455
Discount rate………………………...…………….......
Future salary increases……………………………....
Future pension increases…………………...………..
Turnover, on average…………………………………
1.20%
1.00%
0.00%
12.50%
2.15%
1.50%
1.00%
12.50%
December 31, 2014
December 31, 2013
Page 39 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements│Notes
Mortality rate
Assumptions regarding future mortality experience are set based on advice, published statistics and experience. The average life
expectancy in years of a pensioner retiring at age of 65 (male) or 64 (female) on the balance sheet date are as follows:
Male…………………………………………………
Female………………………………………………
2014
21.39
24.84
2013
18.93
22.29
The estimated Group contributions to pension plans for the financial year 2015 amount to CHF18,673.
The categories of plan assets and their corresponding return are as follow:
December 31, 2014
Allocation in %
December 31, 2013
Allocation in %
Cash………………………………………………………
Bonds…………………………………………………….
Shares……………………………………………………
Real estates and mortgage…………………………….
Alternative investments…………………………………
Total………………………………………………..........
1.7%
82.7%
3.5%
12.1%
0.0%
100%
2.5%
83.5%
2.4%
11.4%
0.2%
100%
The following table shows the funding of the defined benefit pensions and actuarial adjustments on plan liabilities:
Present value of defined benefit obligation……………
Fair value of plan assets………………………………...
Deficit in the plan……………………………………….
Experience adjustment…………………………………..
Actuarial losses on plan assets…………….…………..
2014
(2,057,079)
1,912,543
(144,536)
366,589
5,465
2013
(1,739,890)
1,249,455
(490’435)
(170,230)
(36,593)
The following table shows the estimated benefit payments for the next ten years:
2015..…………………………………...
2016...…………………………………..
2017…………………..........................
2018…………………..........................
2019-2023…………...........................
40,823
29,678
25,335
20,964
46,013
22. Finance income and costs
Interest income……………………………………...
Unrealized foreign exchange loss…………………..
Finance result, net...………...……………………..
2014
2013
1,586
20,192
21,778
4,134
(7,367)
(3,233)
Page 40 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements│Notes
23. Loss per share
Basic and diluted earnings per share is calculated by dividing the profit attributable to equity holders of the Company by th e weighted
average number of common shares in issue during the year excluding common shares purchased by the Group and held as treasury
shares.
Loss attributable to equity holders of the Company...
Weighted average number of shares in issue……….
Basic and diluted loss per share…………………..
2014
2013
1,774,858
9,984,888
(0.18)
14,461,828
9,066,087
(1.60)
The Company has one category of dilutive potential shares as at December 31, 2014 and December 31, 2013: equity sharing
certificates (ESCs) and share option. As of December 31, 2014 and December 31, 2013, equity sharing certificates and share options
have been ignored in the calculation of the loss per share, as they would be antidilutive.
24. Commitments and contingencies
Operating lease commitments
Within 1 year……………………………………………..
Later than 1 year and no later than 5 years……...…..
Total operating lease commitments………………..
2014
2013
147,447
—
147,447
1,157,203
2,548,938
3,706,141
Operating lease commitments consist mainly of rental contracts for laboratories, offices and related spaces at Plan-les-Ouates at
December 31, 2014 and 2013, there are no commitments over 5 years.
Capital commitments
As at December 31, 2014 and 2013, the Group has no capital expenditure contracted but not yet incurred.
Contingencies
As part of the ordinary course of business, the Group is subject to contingent liabilities in respect of certain litigation. In the opinion of
management, none of the outstanding litigation will have a significant adverse effect on the Group’s financial position (see note 4.1).
25. Related party transactions
Related parties include members of the Board of Directors and the Executive Management of the Group. The following transactions
were carried out with related parties:
Key management compensation
2014
2013
Salaries and other short-term employee benefits…...
Consulting fees………………………………………….
Post-employment benefits……………………………..
Share-based compensation….………………………..
53,146
676,000
-
274,039
1,003,185
2,496,585
240,000
123,310
76,774
2,936,669
Loans to related parties – Executive Management
2014
2013
At January 1………………………………………..........
Exits from the Executive Management………………..
Loans advanced during the year………………………
Loans written back / (written-off) during the year……
Loans reimbursed during the year…………………….
At December 31………………………………………..
181,474
-
-
(181,474)
-
-
738,660
(568,204)
-
11,018
-
181,474
In 2014, no loans were made to its employees, in connection with the granting of equity sharing certificates, to finance the tax and
social charges consequences of the grant of ESCs. The loans accrue interest at 0.2% per year and the loan principal and accrued
Page 41 of 52
Addex Therapeutics Annual Report 2014 │Consolidated Financial Statements│Notes
interest are repayable from the first capital gains realised from the exercise of the subscription rights attached to the ESCs. Should no
capital gains be realized over the 5 year term of the ESCs then the loans are forgiven.
26. Events after the balance sheet date
On March 9, 2015, the Group issue 1,526,036 new shares from the authorized capital. Of the new shares, 921,667 where placed at
CHF3 per share with investors and 604,369 were placed with Addex Pharma SA at CHF1, and are held as treasury shares.
On January 15, 2015, the Swiss National Bank announced its decision to abandon with immediate effect the euro cap at the
exchange rate of CHF 1.20. As a result, the exchange rate dropped and since then approximates parity to the Swiss franc. Since this
event occurred after the balance sheet date, it does not have any effect on the amounts reported as of December 31, 2014. Had it
occurred on December 31, 2014, the Company would have recorded a foreign exchange loss of approximately CHF 33,833, which
mainly relates to the bank balances and certain accounts payable denominated in euros. The abandonment of the euro cap affected
also the exchange rate USD to Swiss franc by approximately 12%. This would have resulted in an additional foreign exchange loss of
approximately CHF106,905. Bank balances held in euros and US dollars will predominantly be used to settle goods and services that
the Company purchases in these currencies.
There has been no other material event after the balance sheet date.
27. Risk assessment disclosure required by Swiss law
The Chief Executive Officer coordinate and align the risk management processes, and reports to the Board and the Audit Committee
(disbanded on June 27, 2014) on a regular basis on risk assessment and risk management. The organization and the corporate
processes have been designed and implemented to identify and mitigate risks at an early stage. Organizationally, the responsibility
for risk assessment and management is allocated to the Chief Executive Officer and members of the Executive Management and
specialized corporate functions such as Group Finance and the Group Safety Committee. Group Finance provides support and
controls the effectiveness of the risk management processes. Financial risk management is described in more detail in note 3 to the
Group’s consolidated financial statements.
Page 42 of 52
Addex Therapeutics Annual Report 2014
Report of the Statutory Auditor to the General Meeting of Addex Therapeutics Ltd, Geneva
Report of the statutory auditor on the consolidated financial statements
As statutory auditor, we have audited the consolidated financial statements of Addex Therapeutics Ltd, which comprise the balance
sheet, statements of income, statements of comprehensive income, statements of changes in equity, statements of cash flows and
notes, for the year ended 31 December 2014.
Board of Directors’ responsibility
The Board of Directors is responsible for the preparation and fair presentation of the consolidated financial statements in accordance
with the International Financial Reporting Standards (IFRS) and the requirements of Swiss law. This responsibility includes designing,
implementing and maintaining an internal control system relevant to the preparation and fair presentation of consolidated financial
statements that are free from material misstatement, whether due to fraud or error. The Board of Directors is further responsible for
selecting and applying appropriate accounting policies and making accounting estimates that are reasonable in the circumstances.
Auditor’s responsibility
Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in
accordance with Swiss law and Swiss Auditing Standards as well as the International Standards on Auditing. Those standards
require that we plan and perform the audit to obtain reasonable assurance whether the consolidated financial statements are free
from material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial
statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material
misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor
considers the internal control system relevant to the entity’s preparation and fair presentation of the consolidated financial statements
in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
effectiveness of the entity’s internal control system. An audit also includes evaluating the appropriateness of the accounting policies
used and the reasonableness of accounting estimates made, as well as evaluating the overall presentation of the consolidated
financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit
opinion.
Opinion
In our opinion, the consolidated financial statements for the year ended 31 December 2014 give a true and fair view of the financial
position, the results of operations and the cash flows in accordance with the International Financial Reporting Standards (IFRS) and
comply with Swiss law.
Report on other legal requirements
We confirm that we meet the legal requirements on licensing according to the Auditor Oversight Act (AOA) and independence (article
728 CO and article 11 AOA) and that there are no circumstances incompatible with our independence.
In accordance with article 728a paragraph 1 item 3 CO and Swiss Auditing Standard 890, we confirm that an internal control system
exists which has been designed for the preparation of consolidated financial statements according to the instructions of the Board of
Directors.
We recommend that the consolidated financial statements submitted to you be approved.
PricewaterhouseCoopers SA
Michael Foley
Audit expert
Auditor in charge
Geneva, 30 April 2015
Adrien Benoit
Audit expert
Page 43 of 52
Addex Therapeutics Annual Report 2014 │Statutory Financial Statements
Statutory Financial Statements of Addex
Therapeutics Ltd as at December 31, 2014
Page 44 of 52
Addex Therapeutics Annual Report 2014 │Statutory Financial Statements
Balance Sheets as at December 31, 2014 and December 31, 2013
Notes
December
December
31, 2014
31, 2013
Amounts in Swiss francs
ASSETS
Current assets
Cash and cash equivalents……………………………................................................
Other receivables
Third parties…………………………...................................................................
Accrued income…………………...…………………………………………………….....
Total current assets………………………………………………………………….…..
Non-current assets
Investments in Group companies……………...………..............................................
Other non-current assets
Loans to Group companies………………………...............................................
Total non-current assets………………………………………………………………..
6
7
636,916
1,630,569
1,166
17,219
655,301
823
30,606
1,661,998
2
2
1,470,496
1,470,498
2,621,543
2,621,545
Total assets…………………………………………….................................................
2,125,799
4,283,543
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities
Trade payables…...…………………………………….................................................
Other payables: Third parties………………………………………………………….…
Accruals…………………………………………………………………………………..…
Total current liabilities……………………………….................................................
Shareholders’ equity
Share capital………………………………………………………………………………..
Share premium
Treasury shares reserve……………………………………………………………….….
Non-voting equity securities (*)……………………….................................................
Accumulated deficit…………………………………………………………………….….
Total shareholders’ equity……………………………………………………………...
9
11
8
149,430
11,404
215,557
376,391
10,173,576
186,966
250,749
p.m.
(8,861,883)
1,749,408
80,338.
—
226,825
307,163
10,173,576
10,176,933
437,715
p.m.
(16,811,844)
3,976,380
Total liabilities and shareholders’ equity…………………………………………….
2,125,799
4,283,543
(*) p.m. = pro memoria. Non-voting equity securities have no nominal value.
The accompanying notes form an integral part of these financial statements.
Page 45 of 52
Addex Therapeutics Annual Report 2014 │Statutory Financial Statements
Statements of Income for the years ended December 31, 2014 and
2013
Operating expenses
Professional fees……………………………………………….……………….…………...
Other operating expenses…………………………………………………….…………….
Provision for Group companies……………………………………………….……………
Taxes………………………………………………………………………………………….
Total operating expenses…………………………………………………………………
2014
2013
Amounts in Swiss francs
162,631
166,605
1,770,059
128,657
2,227,952
792,317
373,981
15,538,190
109,702
16,814,190
Interest income…….…………………………………………………………………………
(980)
(2,346)
Net loss before taxes………………………………………………………………………
2,226,972
16,811,844
Income tax expense…………....……………………………………………………………
—
—
Net loss for the year……………………………………………..…………………………
2,226,972
16,811,844
The accompanying notes form an integral part of these financial statements.
Page 46 of 52
Addex Therapeutics Annual Report 2014 │Statutory Financial Statements
Notes to the Financial Statements for the years
ended December 31, 2014 and 2013
(amounts in Swiss francs)
1. General
Addex Therapeutics Ltd, formerly Addex Pharmaceuticals Ltd, was founded on February 19, 2007.
2. Guarantees, other indemnities and assets pledged in favor of third parties
As of December 31, 2014 and December 31, 2013, there were no guarantees, other indemnities or assets pledged in favor
of third parties.
3. Pledges on assets to secure own liabilities
As of December 31, 2014 and December 31, 2013, there were no assets pledged to secure own liabilities.
4. Lease commitments not recorded in the balance sheet
As of December 31, 2014 and December 31, 2013, there were no lease commitments not recorded in the balance sheet.
5. Amounts due to pension funds
As of December 31, 2014 and December 31, 2013, there were no amounts due to pension funds.
6. Significant investments
Addex Therapeutics Ltd as a holding company for the Addex Therapeutics Group owns:
Company
Addex Pharma SA,
Plan-les-Ouates, Switzerland
Addex Pharmaceuticals France SAS,
Archamps, France
Business
Capital
Research & development
CHF3,987,492
Research & development
€37,000
Interest in
capital in %
100%
100%
As at December 31, 2014 and 2013, the Company has provided for its investments in Group companies as follows:
Investment in Addex Pharma SA………………………..
Provision for investment in Addex Pharma SA…………
Investment in Addex Pharmaceuticals France SAS……..
December 31, 2014
December 31, 2013
3,987,492
(3,987,491)
1
2
3,987,492
(3,987,491)
1
2
7. Other non-current assets – Loans to Group companies
As at December 31, 2014 and 2013, the Company has provided for its loan to Addex Pharma SA as follows:
Loan to Addex Pharma SA………………………………
Provision for loan to Addex Pharma SA………………...
December 31, 2014
December 31, 2013
157,710,319
(156,239,823)
1,470,496
157,091,308
(154,469,765)
2,621,543
The loan to Addex Pharma SA is subordinated to the claims of other creditors of the subsidiary up to CHF156,239,823.
Page 47 of 52
Addex Therapeutics Annual Report 2014 │Statutory Financial Statements│Notes
8. Equity
Share
capital
General reserve, from…
…retained
…capital
earnings
contribution
Treasury
shares
reserve
Accumulated
deficit
Total
January 1, 2013……………..
Issue of shares, capital
9,002,964
161,607,712
(97,172,243)
489,531
(56,358,923)
17,569,041
increase…………………….
1,170,612
2,048,571
—
—
3,219,183
Offset accumulated deficit
with general reserve……….
Transfer from treasury shares
reserve……………………...
Net loss of the
year………………………….
December 31, 2013…………
Issue of shares, capital
increase…………………….
Offset accumulated deficit
with general reserve….…...
Transfer from treasury shares
reserve…………………......
Net loss of the
year………………………....
December 31, 2014……..…..
—
—
—
—
(56,358,923)
51,816
—
—
—
—
—
56,358,923
(51,816)
—
—
(16,811,844)
(16,811,844)
10,173,576
163,708,099
(153,531,166)
437,715
(16,811,844)
3,976,380
—
—
—
—
—
—
—
(10,176,933)
—
—
—
10,176,933
186,966
—
—
—
(186,966)
—
—
(2,226,972)
(2,226,972)
—
—
—
—
—
10,173,576
163,895,786
(163,708,099)
250,749
(8,861,883)
1,749,408
On August 9, 2013, the Group issued 1,170,612 new shares at CHF1 from the authorized capital for use in a private
placement for CHF2.75 per share. The gross proceeds of CHF3,219,183 have been recorded in share capital for
CHF1,170,612 and in general reserve from capital contributions for CHF2,048,571.
At December 31, 2014, the total outstanding share capital is CHF10,173,576 (December 31, 2011: CHF10,173,576),
consisting of 10,173,576 shares (December 31, 2013: 10,173,576). All shares have a nominal value of CHF1 and are fully
paid. The authorized capital and conditional capital as at December 31, 2014 and 2013 are as follows:
Authorized capital……………………………………….
Conditional capital………………………………………
5,086,788
4,485,921
3,325,683
4,485,921
December 31, 2014
December 31, 2013
9. Treasury share reserve
This reserve corresponds to the purchase price of shares in Addex Therapeutics Ltd held by Group companies. The table
shows movements in the number of shares and the treasury share reserve:
Number of
registered shares
Price in CHF
Total purchase
price in CHF
Balance at January 1, 2013…….
Purchases ………………………..
Balance at December 31, 2013…
Net sales……………………………
Balance at December 31, 2014…
369,433
(39,104)
330,329
(141,641)
188,688
1.33
1.32
489,531
(51,816)
437,715
(186,966)
250,749
% of share
capital
4.10%
4.30%
2.46%
Page 48 of 52
Addex Therapeutics Annual Report 2014 │Statutory Financial Statements│Notes
10. Significant shareholders
According to the information available to the Board of Directors the following shareholders held shares entitling them to more
than 3% of the total voting rights:
December 31, 2014
December 31, 2013
Number of
shares
Interest in
capital in %
Number of
shares
Interest in
capital in %
BVF Partners L.P.*…………….......
Tim Dyer(1)………………………….
Sofinnova Capital IV FCPR…….…
TVM V Life Science Ventures…....
Visium Asset Management, L.P.....
Varuma AG…………………………
2,503,849
594,906
311,667
—
—
—
24.61%
5.85%
3.06%
—%
—%
—%
2,755,249
—
806,648
690,525
488,114
413,243
27.09%
—
7.93%
6.79%
4.80%
4.06%
*Addex Therapeutics Ltd shares were held by several related entities.
(1) the shareholding of Tim Dyer assumes the exercise of all equity incentive units at the 31 December 2014.
11. Non-voting equity securities
Refer to note 15 of the consolidated financial statements.
12. Board of Directors and Executive Management shareholdings and equity incentive unites
As of December 31, 2014, members of the Board of Directors and Executive Management held the following shares in the
Company:
Vincent Lawton, Chairman…………………………………..
Sonia Poli, Chief Scientific Officer………………………….
Timothy Dyer, Chief Executive Officer……………………..
Number of Shares
500
17,000
86,906
As of December 31, 2013, members of the Board of Directors and Executive Management held the following shares in the
Company:
André Mueller, Chairman…..………………………………..
Vincent Lawton, Vice-Chairman……..……………………..
Sonia Poli, Chief Scientific Officer………………………….
Timothy Dyer, Chief Executive Officer……………………..
Number of Shares
75,126
500
17,000
33,175
As of December 31, 2014, members of the Board of Directors and Executive Management held the following equity incentive
units in the Company:
Vincent Lawton, Chairman……………...
Sonia Poli, Chief Scientific Officer……...
Tim Dyer, Chief Executive Officer…
Number of
vested equity
incentive units
0
0
158,000
Number of
unvested equity
incentive units
94,000
100,000
350,000
Total number of
equity incentive
units
100,000
100,000
408,000
As of December 31, 2013, members of the Board of Directors and Executive Management held the following equity incentive
units in the Company:
André Mueller, Chairman..……………...
Vincent Lawton, Vice-Chairman…...…...
Sonia Poli, Chief Scientific Officer……...
Tim Dyer, Chief Executive Officer…
Number of
vested equity
incentive units
7,875
5,250
50,675
108,000
Number of
unvested equity
incentive units
1,125
750
16,175
0
Total number of
equity incentive
units
9,000
6,000
66,850
108,000
13. Risk assessment
Refer to note 27 of the consolidated financial statements.
Page 49 of 52
Addex Therapeutics Annual Report 2014 │Statutory Financial Statements│Notes
14. Uncertainties and ability to continue operations
The Company’s ability to continue operations is highly dependent on the Group’s ability to continue as a going concern. The
Group is a development stage enterprise and is exposed to all the risks inherent in establishing a business. Inherent in the
Group’s business are various risks and uncertainties, including the substantial uncertainty that current projects will succeed.
The Group’s success may depend in part upon its ability to (i) establish and maintain a strong patent position and protection,
(ii) enter into collaborations with partners in the pharmaceutical industry, (iii) acquire and retain key personnel, and (iv)
acquire additional capital to support its operations. As at December 31, 2014, there is significant uncertainty with respect to
the Group’s ability to continue as a going concern. After considering the Group’s cash position in light of current financial
plans and financial commitments, the Board of Directors believes the Group and therefore the Company will be able to meet
all of its obligations for a further 12 months as they fall due and, hence, the financial statements have been prepared on a
going concern basis. The Group is currently engaged in a number of activities to ensure that it can continue its operations,
including monetizing its assets, raising additional capital, pursuing strategic alternatives and evaluating restructuring options.
The outcome of these activities is inherently uncertain and had the Board assessed differently the ability of the Group to
execute on its current financial plans and the ability of the Company to meet all of its obligations for a further 12 months then
the Company would have presented the financial statements on a liquidation basis. Had the financial statements been
prepared on a liquidation basis then certain commitments and contingencies would have been recorded on the balance
sheet and certain assets would have been written down to their recoverable amounts.
Proposal of the Board of Directors for appropriation of loss carried forward
The Board of Directors proposes to transfer CHF186,966 from the treasury shares reserve to the general reserve from
capital contribution and to carry forward the net loss for the year 2014 of CHF2,226,972.
Page 50 of 52
Addex Therapeutics Annual Report 2014 │Statutory Financial Statements
Report of the statutory auditor to the General Meeting of Addex Therapeutics Ltd, Geneva
Report of the statutory auditor on the financial statements
As statutory auditor, we have audited the financial statements of Addex Therapeutics Ltd, which comprise the balance sheets,
statements of income and notes, for the year ended 31 December 2014.
Board of Directors’ responsibility
The Board of Directors is responsible for the preparation of the financial statements in accordance with the requirements of Swiss
law and the company’s articles of incorporation. This responsibility includes designing, implementing and maintaining an internal
control system relevant to the preparation of financial statements that are free from material misstatement, whether due to fraud
or error. The Board of Directors is further responsible for selecting and applying appropriate accounting policies and making
accounting estimates that are reasonable in the circumstances.
Auditor’s responsibility
Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in
accordance with Swiss law and Swiss Auditing Standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance whether the financial statements are free from material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements.
The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the
financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers the internal control
system relevant to the entity’s preparation of the financial statements in order to design audit procedures that are appropriate in
the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control system. An
audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of accounting
estimates made, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence we
have obtained is sufficient and appropriate to provide a basis for our audit opinion.
Opinion
In our opinion, the financial statements for the year ended 31 December 2014 comply with Swiss law and the company’s articles
of incorporation.
Report on other legal requirements
We confirm that we meet the legal requirements on licensing according to the Auditor Oversight Act (AOA) and independence
(article 728 CO and article 11 AOA) and that there are no circumstances incompatible with our independence.
In accordance with article 728a paragraph 1 item 3 CO and Swiss Auditing Standard 890, we confirm that an internal control
system exists which has been designed for the preparation of financial statements according to the instructions of the Board of
Directors.
We recommend that the financial statements submitted to you be approved.
Further, we draw attention to the fact that half of the share capital and the legal reserves are no longer covered (article 725 para.
1 CO).
PricewaterhouseCoopers SA
Michael Foley
Audit expert
Auditor in charge
Geneva, 30 April 2015
Adrien Benoit
Audit expert
Page 51 of 52
Addex Therapeutics Annual Report 2014 │Statutory Financial Statements
Forward Looking Statements
These materials contain forward-looking statements that can be identified by terminology such as “not approvable”, “continue”,
“believes”, “believe”, “will”, “remained open to exploring”, “would”, “could”, or similar expressions, or by express or implied
discussions regarding Addex Therapeutics, formerly known as, Addex Pharmaceuticals, its business, the potential approval of its
products by regulatory authorities, or regarding potential future revenues from such products. Such forward-looking statements
reflect the current views of Addex Therapeutics regarding future events, future economic performance or prospects, and, by their
very nature, involve inherent risks and uncertainties, both general and specific, whether known or unknown, and/or any other
factor that may materially differ from the plans, objectives, expectations, estimates and intentions expressed or implied in such
forward-looking statements. Such may in particular cause actual results with allosteric modulators of mGlu2, mGlu4, mGlu5,
mGlu7, GABA-BR or other therapeutic targets to be materially different from any future results, performance or achievements
expressed or implied by such statements. There can be no guarantee that allosteric modulators of mGlu2, mGlu4, mGlu5, mGlu7,
GABA-BR or other therapeutics targets will be approved for sale in any market or by any regulatory authority. Nor can there be
any guarantee that allosteric modulators of mGlu2, mGlu4, mGlu5, mGlu7, GABA-BR or other therapeutic targets will achieve any
particular levels of revenue (if any) in the future. In particular, management’s expectations regarding allosteric modulators of
mGlu2, mGlu4, mGlu5, mGlu7, GABA-BR or other therapeutic targets could be affected by, among other things, unexpected
actions by our partners, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial
results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general;
government, industry and general public pricing pressures; the company’s ability to obtain or maintain patent or other proprietary
intellectual property protection. Should one or more of these risks or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Addex Therapeutics is
providing the information in these materials as of this date and does not undertake any obligation to update any forward-looking
statements contained in these materials as a result of new information, future events or otherwise, except as may be required by
applicable laws.
For more information about the Addex Therapeutics Ltd Group please contact:
Addex Therapeutics
14 Chemin des Aulx
1228 Plan-les-Ouates, Geneva
Switzerland
Investor & Media Relations
Tel: +41 22 884 15 55
Fax: +41 22 884 15 56
investor.relations@addextherapeutics.com
media.relations@addextherapeutics.com
Share Registry
SharecommServices AG
Tel: +41 44 809 58 58
Fax: +41 44 809 58 59
General Information
Tel: +41 22 884 15 55
Fax: +41 22 884 15 56
info@addextherapeutics.com
Addex on the Internet
www.addextherapeutics.com
Page 52 of 52